

## AHA POLICY STATEMENT

# Call to Action to Prevent Venous Thromboembolism in Hospitalized Patients

## A Policy Statement From the American Heart Association

**ABSTRACT:** Venous thromboembolism (VTE) is a major preventable disease that affects hospitalized inpatients. Risk stratification and prophylactic measures have good evidence supporting their use, but multiple reasons exist that prevent full adoption, compliance, and efficacy that may underlie the persistence of VTE over the past several decades. This policy statement provides a focused review of VTE, risk scoring systems, prophylaxis, and tracking methods. From this summary, 5 major areas of policy guidance are presented that the American Heart Association believes will lead to better implementation, tracking, and prevention of VTE events. They include performing VTE risk assessment and reporting the level of VTE risk in all hospitalized patients, integrating preventable VTE as a benchmark for hospital comparison and pay-for-performance programs, supporting appropriations to improve public awareness of VTE, tracking VTE nationwide with the use of standardized definitions, and developing a centralized data steward for data tracking on VTE risk assessment, prophylaxis, and rates.

Peter K. Henke, MD,  
FAHA, Chair  
Susan R. Kahn, MD, MSc,  
FRCP  
Christopher J. Pannucci,  
MD, MS  
Eric A. Secemsky, MD  
Natalie S. Evans, MD,  
FAHA  
Alok A. Khorana, MD  
Mark A. Creager, MD,  
FAHA  
Aruna D. Pradhan, MD,  
MPH, FAHA  
On behalf of the  
American Heart  
Association Advocacy  
Coordinating  
Committee

**A**cute venous thromboembolism (VTE), comprising deep venous thrombosis (DVT) of the legs or pelvis and pulmonary embolism (PE), is a frequent complication in hospitalized patients, a leading contributor to increased length of stay, and the leading cause of preventable hospital death in the United States and worldwide.<sup>1-5</sup> About two-thirds of patients with VTE present with DVT only. The remaining present with PE as the first manifestation and primary cause of VTE-related mortality.<sup>6</sup> Most estimates place the US annual incidence of clinically validated (ie, objectively diagnosed) VTE in adults at 1 to 2 per 1000 per year,<sup>1,7-10</sup> with an exponential increase with age from 1 per 10000 in young adults to 1 per 100 in the elderly.<sup>6</sup> Data from 2 large US cohorts<sup>11</sup> place the estimated absolute lifetime risk of VTE after 45 years of age at 8.1% (95% CI, 7.1-8.7) overall, 11.5% in blacks, 10.9% in obese individuals, 17.1% among those with the factor V Leiden mutation, and 18.2% among blacks with sickle cell trait. Despite the importance of this disease, there are few contemporary investigations of the total number of VTE events (incident and recurrent) occurring in the United States annually because national surveillance is not performed. The data are thus imprecise, with most prior epidemiological studies limited by small sample size, geographic constraints, or reliance on administrative databases with variable data quality for case ascertainment.

Hospital-acquired VTE, the focus of this report, is commonly defined as VTE occurring during or within 3 months after hospitalization and accounts for >50% of

**Key Words:** AHA Scientific Statements  
■ epidemiologic studies  
■ inpatients ■ pulmonary embolism  
■ risk assessment ■ venous thromboembolism ■ venous thrombosis

© 2020 American Heart Association, Inc.

<https://www.ahajournals.org/journal/circ>

the population burden of VTE in the United States.<sup>12–16</sup> Abundant evidence from multiple randomized clinical trials conducted over the past 3 decades conclusively demonstrates that appropriate use of primary thromboprophylaxis in high-risk hospitalized medical and surgical patients is safe, clinically effective, and cost-effective for reducing VTE.<sup>17–22</sup> However, despite these data and the publication of numerous evidence-based consensus guidelines,<sup>23–33</sup> thromboprophylaxis remains either underused or misapplied,<sup>34–47</sup> and population-based studies have shown no temporal declines in either VTE incidence<sup>1,4,48</sup> or case fatality.<sup>49–54</sup> Compounding these issues, public and provider awareness of VTE is low and lags behind that of other common diseases.<sup>55</sup>

Given that much of the morbidity and mortality from VTE are preventable, increased VTE awareness and prioritization of proven, evidence-based primary prevention strategies accompanied by uniform tracking of hospital-acquired VTE should be a national health priority. Indeed, a recent Agency for Healthcare Research and Quality–sponsored study group included interventions to improve prophylaxis rates for VTE as a safety strategy that are ready for adoption now.<sup>56</sup> The purpose of this report is to review the currently understood VTE risk factors, evidence-based guidelines for hospital-based VTE risk assessment and prophylaxis, and current quality measures for VTE prevention. We then propose several policy recommendations that regulatory officials, government, and payers can adopt to reduce the occurrence and impact of this disease.

The call to action is to reduce hospital-acquired VTE by 20% by the year 2030. This call to action grew organically from a summit held at the 2017 American Heart Association (AHA) Arteriosclerosis, Thrombosis and Vascular Biology/Peripheral Vascular Disease Scientific Sessions, during which multiple experts in peripheral vascular disease gathered to discuss population health priorities in peripheral vascular disease. The venous group discussed multiple issues and topics related to VTE and, from the whole group input, came up with what is felt to be a realistic and achievable goal.

## COST AND DIAGNOSIS OF VTE

Costs associated with VTE treatment can be used to assess the potential economic benefit of prevention efforts. As recently reported, treatment for acute VTE is estimated to incur direct medical costs of \$12 000 to \$15 000 (2014 US dollars) per individual in first-year survivors. Approximately 18% of patients with VTE are readmitted within 30 days at a cost of nearly \$10 000 per patient,<sup>57</sup> and between 10% and 30% of acute VTE survivors develop recurrent VTE within 5 years, with a peak after discontinuation of anticoagulation.<sup>58</sup> Patients developing VTE often have multiple comorbidities that individually contribute to healthcare use. However,

as recently demonstrated, the incremental costs of hospital-related VTE are significant beyond those attributable to coexistent health conditions.<sup>59</sup> Cost estimates commonly exclude subsequent VTE-related morbidity. These include postthrombotic syndrome, occurring in 30% to 50% of patients after proximal DVT,<sup>60</sup> and chronic thromboembolic pulmonary hypertension, occurring in 4% within 2 years of PE survival.<sup>61</sup> When these additional events are factored into cost models, the projected annual cost of preventable hospital-acquired VTE is \$7 to \$10 billion per year.<sup>7</sup>

Accurate diagnosis is essential to gauge the success of prevention efforts. The diagnosis of VTE is challenging because clinical features are nonspecific and testing can be either falsely positive or falsely negative. Thus, both clinical assessment and objective testing are required. Risk scores for suspected VTE incorporate clinical assessment of pretest probability (PTP) of disease. Although there are several PTP scoring systems, the Wells DVT score, the Wells PE score, and the Geneva PE score are the most widely used and best validated.<sup>62–65</sup> Although PTP assessment alone cannot rule in VTE and generally does not safely rule out VTE, selection of diagnostic tests should align with prior probability (eg, confirmatory testing if high PTP or exclusionary testing if low PTP). Patients with low PTP and a negative quantitative D-dimer can have VTE excluded without the need for imaging. Confirmatory imaging, when required, includes compression ultrasonography, computed tomography angiography, ventilation-perfusion scintigraphy or single-photon emission tomography, magnetic resonance angiography, and echocardiography.

The impact of newer testing modalities is worth mentioning. Data pertaining to this issue derive largely from the Nationwide Inpatient Sample, a weighted sample of US hospital admission data since the 1990s prepared by the Healthcare Cost and Utilization Project. Nationwide Inpatient Sample data consistently show an increasing number of hospitalizations with either a principal or any diagnosis of PE, coinciding with increased availability and use of computed tomography angiography in the late 1990s.<sup>66,67</sup> Stein et al,<sup>54</sup> analyzing Nationwide Inpatient Sample data, found that despite the increasing number of admissions for PE, the percentage of admissions meeting criteria for massive PE has declined, as have hospital length of stay and in-hospital PE mortality, suggesting increasing diagnosis and admission for submassive PE. The clinical significance of subsegmental PE detected by more sensitive chest imaging or of isolated distal DVT detected by whole-leg ultrasound is unknown, and whether treatment benefits outweigh risks is controversial because of the lack of natural history data on the risk of progression, recurrence, chronic sequelae, and bleeding risk in these patients.

Lastly, the issue of surveillance bias related to VTE imaging diagnosis is significant.<sup>68</sup> That is, a lower

threshold for using duplex ultrasonography will detect a significantly greater number of DVTs, but it is unclear whether this correlates with quality of care at a given institution.<sup>69</sup> For example, data from >2500 hospitals with variable VTE prophylaxis and diagnostic imaging rates demonstrate that high-quality hospitals with high prescription of VTE prophylaxis also had higher risk-adjusted VTE rates resulting, in part, from a lower threshold for duplex scanning.<sup>70</sup> Currently, there are no explicit standards or indications for ordering imaging tests to confirm or exclude a VTE outside of clinical judgment. Furthermore, because vigilant care, adherence to hospital screening programs, and more widespread VTE imaging detect asymptomatic disease, health outcomes and costs must be ascertained.

## COMMON MEDICAL ILLNESSES ASSOCIATED WITH VTE

Risk factors for acute VTE among hospitalized patients have been extensively investigated and include both inherited and acquired conditions. Major demographic risk factors include older age and obesity.<sup>71,72</sup> Although not an exhaustive list of medical illnesses that are associated with VTE, some prototypical examples follow.

Infection may be a major contributor to VTE. Hospitalization for acute infection has consistently been related to the development of VTE.<sup>72</sup> In a case-control study of >1300 patients with acute VTE in Minnesota, 39.4% of cases were hospitalized with infection compared with 12.7% of control subjects ( $P<0.001$ ).<sup>73</sup> In adjusted analysis, intra-abdominal infection was associated with the greatest risk (odds ratio [OR], 17.8), followed by oral infection (OR, 11.6) and sepsis (OR, 10.7). Symptomatic urinary tract infections and pneumonia were also significant risk factors. Even among those who receive adequate prophylaxis, patients with infections remain at risk for VTE. For example, in a multicenter analysis of 113 patients in the intensive care unit undergoing treatment for severe sepsis, the incidence of acute VTE was 37.2% despite the fact that all patients received thromboprophylaxis, although these patients were all screened for VTE.<sup>74</sup>

Acute stroke is another recognized risk factor for VTE. In an analysis of >30 000 patients in Norway, ischemic stroke was associated with a 3-fold greater risk of VTE compared with no stroke.<sup>75</sup> The highest risk occurred within the first month of the event (hazard ratio, 19.7). These events have important prognostic implications; up to 25% of early deaths after stroke are caused by acute PE.<sup>76</sup> Patients admitted with congestive heart failure are also particularly susceptible to acute VTE<sup>77</sup> because of the condition itself and shared comorbid conditions associated with VTE.<sup>78,79</sup> Furthermore, the risk of VTE has been associated with increasing disease

severity, as determined by either left ventricular ejection fraction or NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels.<sup>80,81</sup>

Although not unique to patients hospitalized with the condition, inflammatory bowel disease (IBD) is a significant risk factor for VTE, reflecting an association between inflammation and thrombosis.<sup>82</sup> In multiple large studies, IBD has been shown to increase the risk of VTE by 1.5- to 3.5-fold<sup>83</sup> and correlates with disease activity. Unlike the general at-risk population, patients with IBD often experience thromboembolic events at a younger age,<sup>82</sup> and VTE mortality in patients with IBD is high, with diagnosed IBD conferring an independent 2.5-fold greater mortality.<sup>84</sup> Abnormalities in inflammation and coagulation also may contribute to acute VTE in patients with autoimmune and rheumatological disorders.<sup>85,86</sup> Among all autoimmune diseases, there is a 3-fold increased risk of acute VTE, which is greater among those with active systemic disease.<sup>87</sup> In particular, the odds of developing acute VTE are highest among those with systemic lupus erythematosus (OR, 15.2) and systemic sclerosis (OR, 7.4).<sup>87</sup> Recurrence rates are elevated in such patients, with a 5-year recurrence risk of up to 40%.<sup>86</sup>



## MALIGNANCY AND VTE RISK

Cancer accounts for one-fifth of all cases of incident VTE. Across all patients with cancer, the risk for VTE is elevated up to 7-fold over patients without cancer; in certain subgroups such as those with pancreatic cancer or primary brain tumors, the risk for VTE may be increased up to 28-fold.<sup>88</sup> Hospitalization is a major risk factor for VTE in patients with cancer. In a recent large US analysis of nearly 6 million hospitalizations for cancer, VTE was observed in 8.4%.<sup>89</sup> In-hospital mortality occurred in 5.5% of patients with cancer without a VTE diagnosis, in 15.0% of those with any VTE, and in 19.4% of those with PE. Furthermore, analyses of temporal data show that the rate of VTE in hospitalized patients with cancer has nearly doubled in recent years, from 3.5% in 1995 to 6.5% in 2012. The risk of VTE was highest in patients with gastrointestinal, ovarian, lung, and esophageal cancers. Comorbid conditions were contributing factors, with VTE rates increasing progressively from 2.3% in those with no comorbidities to >11% in those with  $\geq 3$  major comorbidities. Chemotherapy is a known risk factor for outpatient VTE, but it is unclear whether brief elective admission for chemotherapy truly increases risk. A risk tool has been validated in the hospitalized cancer population in 2 recent cohort studies and incorporates variables such as the site of cancer, elevated leukocyte and platelet counts, low hemoglobin, and high body mass index.<sup>90,91</sup>

Despite the known high risk of VTE in hospitalized patients with cancer and increased mortality risk, patients with cancer are less likely to receive prophylaxis. In an analysis of 2.5 million hospital discharges, hospitalized patients with cancer had the lowest rates of prophylaxis compared with patients with other conditions such as myocardial infarction or severe lung disease.<sup>92</sup> Even when VTE prophylaxis was administered to hospitalized patients with cancer, it was frequently not targeted to those at highest risk.<sup>93</sup> This practice may reflect insufficient clinical trial evidence in this patient population. Specifically, although there are emerging data evaluating the benefit of direct oral anticoagulant use in thromboprophylaxis in outpatients with cancer,<sup>94,95</sup> no cancer-specific randomized trials have evaluated the benefit and risk of inpatient thromboprophylaxis in this population.

### COMMON SURGICAL PROCEDURES ASSOCIATED WITH VTE

Overall rates of provoked VTE resulting from surgical procedures account for 20% of all VTE.<sup>7</sup> In addition to procedure type and duration, patient factors such as age and comorbidities, malignancy, prior VTE, and infectious complications all play a major role in postsurgical VTE risk. Older estimates of symptomatic VTE within 90 days after surgery are 0.7% to 0.9% of 1.65 million cases.<sup>96</sup> Contemporary data, based on the American College of Surgeons National Surgical Quality Improvement Program, estimate the rates of VTE to be between 0.5% and 1.6%.<sup>97–100</sup> A higher VTE incidence of 2% to 3% is observed after neurological, orthopedic, oncological, trauma, and emergency surgery.<sup>96,101</sup> Interruptions or delays in prescription of VTE pharmacoprophylaxis in surgical patients have been shown to be associated with a 2- to 3-fold increased risk of VTE,<sup>102</sup> and 35% to 56% of VTE events occur after discharge.<sup>96,103,104</sup>

Surgical risk per se, namely risk attributed to the procedure itself distinct from other factors, is difficult to ascertain because of several factors. First, most patients are now treated with some form of VTE prophylaxis, and it is unethical to withhold prophylaxis from at-risk patients. Second, the type, dosing, and compliance with VTE prophylaxis are less often available from the considerable number of observational studies providing VTE rates compared with fewer controlled clinical trials, thus obscuring the true incidence. Third, postoperative patients are not uniformly and prospectively imaged for DVT, and the trigger for testing is variable from physician to physician.

Comparative differences in VTE rates between nonhospitalized and hospitalized surgical patients are also somewhat difficult to assess on a population basis, in part because of significant differences in patient factors

that heighten risk independently of hospitalization.<sup>12,71</sup> Similarly, VTE rates vary between hospitalized surgical and medically ill patients, but these differences attributable to surgery become obscured because many surgical patients have comorbid medical illnesses that contribute to VTE risk. One series comparing VTE risks in medical and surgical patients showed that surgical patients were more likely to have a central venous access but less likely to be receiving active chemotherapy.<sup>105</sup> However, these issues are probably clinically relevant only when a VTE risk assessment tool is chosen, as discussed in the next sections.

### LACK OF PATIENT AWARENESS OF VTE AND RISKS

Patient awareness of the risk of VTE associated with hospitalization is low. In a large global survey conducted in 2014, the proportions of respondents who were aware of thrombosis, DVT, and PE (68%, 44%, and 54%, respectively) were lower than the proportions who were aware of other thrombotic disorders such as heart attack and stroke (88% and 85%, respectively) and of nonthrombotic conditions such as hypertension and AIDS (90% and 87%, respectively).<sup>55</sup> Fewer than half of respondents were aware that blood clots were preventable, and awareness that conditions such as cancer, hospitalization, and surgery were associated with risk was quite low (16%, 25%, and 36%, respectively). A similar low awareness was reported in national surveys conducted in individual countries.<sup>106–108</sup> This lack of awareness is not the result of a lack of interest on the part of patients or their families. A survey of patients and families contacted via membership of stakeholder organizations found that participants wanted to learn about VTE symptoms, risk factors, prevention, and complications,<sup>109</sup> preferring to receive education in the context of a doctor-patient encounter. Global initiatives to improve awareness of VTE risk such as World Thrombosis Day<sup>110</sup> reach a large and diverse audience, yet sustainable achievements in symptom recognition, health behaviors, and public perception for patient support and education will require powerful partnerships across public health, clinical practice, and private sectors.

### EVIDENCE BASIS FOR VTE RISK ASSESSMENT AND PROPHYLAXIS

Multiple scientific bodies have made recommendations for VTE prevention. The most widely cited guideline is from the American College of Chest Physicians (ACCP), which gives guidance for medical and surgical patients<sup>111</sup> and was published in 2012. The Antithrombotic Therapy for VTE Disease section was updated in

**Table 1. Summary of 2012 ACCP Guideline Key Recommendations**

For patients at low risk for VTE, prophylaxis is not recommended.
For patients at high or moderate risk for VTE, pharmacological or mechanical prophylaxis is recommended over no prophylaxis.
For patients at high risk for bleeding, pharmacological prophylaxis is not recommended. Instead, such patients should receive mechanical prophylaxis, which can be replaced with pharmacological prophylaxis if the risk of VTE persists and the risk of bleeding decreases.
Duration of guideline recommended prophylaxis:
Medical patients should receive pharmacological prophylaxis for 6–21 d or until discharge from hospital, whichever comes first.
Medical patients should not receive extended prophylaxis beyond the period of patient immobilization or short-term hospital stay.
Surgical patients undergoing major surgery should receive pharmacological prophylaxis for 10–14 d.
The highest-risk surgical patients such as those undergoing abdominal or pelvic surgery for cancer should receive extended prophylaxis (4 wk).
Patients undergoing major orthopedic surgery should receive thromboprophylaxis for a minimum of 10–14 d.
Extended prophylaxis (up to 35 d) is suggested for those undergoing major orthopedic surgery.

ACCP indicates American College of Chest Physicians; and VTE, venous thromboembolism.

2016,<sup>112</sup> although no changes in assessment of risk or prophylaxis were made. Other documents have been issued by the American College of Physicians, American Society of Clinical Oncology, American Society of Hematology, American Academy of Orthopaedic Surgeons, Society of Gynecologic Surgeons, Eastern Association for the Surgery of Trauma, Trauma Quality Improvement Program, and others.<sup>24,33,113–117</sup>

The 2012 ACCP clinical practice guidelines for the prevention of VTE moved clinical practice away from the traditional formula of universal thromboprophylaxis for all hospitalized patients (Table 1). Instead, this edition explicitly advocated prevention strategies that are driven by patients' VTE risk scores, namely the adoption of risk stratification to guide clinicians' decisions to prescribe thromboprophylaxis. For example, in the guideline recommendations for VTE prevention in nonorthopedic surgical patients, patient-oriented VTE risk calculators such as the Caprini and Rogers scores were adopted (see Risk Assessment Tools).<sup>26</sup> For VTE prevention in non-surgical patients, risk stratification with the Padua Prediction Score risk assessment model was advocated.<sup>28</sup> Since that time, additional risk stratification models for hospitalized medical patients have become available, including the IMPROVE score (International Medical Prevention Registry on Venous Thromboembolism).<sup>118</sup>

Individualized VTE risk stratification allows providers to identify patients who have a favorable risk/benefit ratio for pharmacological prophylaxis but also those patients whose risk/benefit relationship is unfavorable or unknown. These findings, as a whole, challenge the concept that all patients require pharmacological prophylaxis and support a more individualized approach to

VTE prophylaxis strategy. Thus, currently recommended prophylaxis strategies become more aggressive as risk level increases, with recommended interventions ranging from no prophylaxis required to mechanical prophylaxis, pharmacological prophylaxis, and then combined mechanical-pharmacological prophylaxis. However, no specific numerical values derived from VTE risk assessments have specific levels of prophylaxis regimens that have been tested in a randomized fashion. Extended-duration prophylaxis (28–35 days) is recommended for the highest-risk surgical patients, although these recommendations are based on older studies that screened asymptomatic patients.

Although the 2012 ACCP guidelines do not recommend performing screening duplex ultrasound in patients without symptoms, other groups suggest that certain populations such as trauma patients may benefit.<sup>119</sup> Another group studied and at high VTE risk includes adult patients in the intensive care unit, in whom standardized surveillance was associated with 52% decreased PE.<sup>120</sup> More data in selected high-risk groups are needed to determine evidence for or against standard screening.

For outpatients, including ambulatory patients and those recently discharged from the hospital, the 2012 ACCP guidelines recommend pharmacological prophylaxis only for patients with solid tumors with additional VTE risk factors who are also at low risk for bleeding. However, the American Society of Clinical Oncology does not specifically recommend discharge VTE prophylaxis.<sup>121</sup> Since the 2012 ACCP guidelines were published, 1 updated systematic review and meta-analysis in acutely ill medical patients (16 studies, 34 369 patients) has confirmed that unfractionated heparin significantly reduced the odds of DVT (OR, 0.38 [95% CI, 0.29–0.51];  $P<0.00001$ ) and PE (OR, 0.65 [95% CI, 0.41–1.00];  $P=0.05$ ) at a cost of increased major hemorrhage (OR, 1.81 [95% CI, 1.10–2.98];  $P=0.02$ ). In addition, low-molecular-weight heparin (LMWH) compared with unfractionated heparin significantly reduced the risk for DVT (OR, 0.77 [95% CI, 0.62–0.96];  $P=0.02$ ) and major bleeding (OR, 0.43 [95% CI, 0.22–0.83];  $P=0.01$ ).<sup>122</sup>

### National Institute for Health and Care Excellence Guidelines 2018

In line with the ACCP clinical practice guidelines, the National Institute for Health and Care Excellence 2018 guidelines on preventing VTE in hospitalized patients include recommendations to manage patients in the hospital and 30 days after discharge from the hospital.<sup>32</sup> Like the ACCP 2012 guidelines, the National Institute for Health and Care Excellence 2018 guidelines also recommend risk assessment to stratify patients' risk of VTE and bleeding and describe interventions to

reduce the incidence of VTE in the hospital and within 90 days after a hospital admission.

### American Society of Hematology Guidelines 2018

The American Society of Hematology, in collaboration with the McMaster GRADE Centre, has recently published guidelines on the prevention, diagnosis, and treatment of VTE, including the prevention of VTE in medically ill patients. Nineteen major recommendations for medically ill patients are provided, including pharmacological prophylaxis for all ill patients, no use in patients in nursing homes, not extending prophylaxis beyond the hospital stay, and aspirin in high-risk patients who cannot receive LMWH or sequential compression devices.<sup>33</sup>

### RISK ASSESSMENT TOOLS AND MODELS

Several risk scores are used for VTE risk assessment in hospitalized patients. The 2005 Caprini DVT Risk Score

(Caprini score) incorporates 40 individual VTE risk factors into a weighted risk model to create an aggregate risk assessment score (Figure 1). This score has been validated to predict a 15- to 20-fold variation in VTE risk among patients undergoing plastic and reconstructive surgery,<sup>124</sup> patients undergoing otolaryngology head and neck surgery,<sup>125</sup> patients receiving gynecology oncology treatment,<sup>126,127</sup> surgical patients in the intensive care unit,<sup>128</sup> and patients undergoing general/vascular/urology surgery.<sup>129</sup>

In addition to identifying baseline risk for VTE, the 2005 Caprini score identifies surgical patients who will or will not benefit from pharmacological prophylaxis. A recent systematic review and meta-analysis specific to the surgical population pooled data from 13 articles (n=14776) and showed that only patients with 2005 Caprini scores of 7 to 8 (OR, 0.60 [95% CI, 0.37–0.97]; P=0.04) and >8 (OR, 0.41 [95% CI, 0.26–0.65]; P<0.001) had significant reduction in rates of perioperative VTE when provided with pharmacological prophylaxis. Patients with Caprini scores ≤6, who made up 75% of the surgical patient population as a whole, had

**Choose All That Apply:**

<p style="text-align: center; background-color: #333; color: white; margin: 0;">Each Risk Factor Represents 1 Point</p> <ul style="list-style-type: none"> <li><input type="checkbox"/> Age 41–60 years</li> <li><input type="checkbox"/> Minor surgery planned</li> <li><input type="checkbox"/> History of prior major surgery (&lt;1 month)</li> <li><input type="checkbox"/> Varicose veins</li> <li><input type="checkbox"/> History of inflammatory bowel disease</li> <li><input type="checkbox"/> Swollen legs (current)</li> <li><input type="checkbox"/> Obesity (BMI &gt;25 kg/m<sup>2</sup>)</li> <li><input type="checkbox"/> Acute myocardial infarction</li> <li><input type="checkbox"/> Congestive heart failure (&lt;1 month)</li> <li><input type="checkbox"/> Sepsis (&lt;1 month)</li> <li><input type="checkbox"/> Serious lung disease including pneumonia (&lt;1 month)</li> <li><input type="checkbox"/> Abnormal pulmonary function (COPD)</li> <li><input type="checkbox"/> Medical patient currently at bedrest</li> <li><input type="checkbox"/> Other risk factors:</li> </ul>	<p style="text-align: center; background-color: #333; color: white; margin: 0;">For Women Only (Each Represents 1 Point)</p> <ul style="list-style-type: none"> <li><input type="checkbox"/> Oral contraceptives or hormone replacement therapy</li> <li><input type="checkbox"/> Pregnancy or postpartum (&lt;1 month)</li> <li><input type="checkbox"/> History of unexplained stillborn infant, recurrent spontaneous abortion (&gt;3), premature birth with toxemia, or growth-restricted infant</li> </ul>
--	---

  

<p style="text-align: center; background-color: #333; color: white; margin: 0;">Each Risk Factor Represents 2 Points</p> <ul style="list-style-type: none"> <li><input type="checkbox"/> Age 60–74 years</li> <li><input type="checkbox"/> Arthroscopic surgery</li> <li><input type="checkbox"/> Malignancy (present or previous)</li> <li><input type="checkbox"/> Major surgery (&gt;45 minutes)</li> <li><input type="checkbox"/> Laparoscopic surgery (&gt;45 minutes)</li> <li><input type="checkbox"/> Patient confined to bed (&gt;72 hours)</li> <li><input type="checkbox"/> Immobilizing plaster cast (&lt;1 month)</li> <li><input type="checkbox"/> Central venous access</li> </ul>	<p style="text-align: center; background-color: #333; color: white; margin: 0;">Each Risk Factor Represents 3 Points</p> <ul style="list-style-type: none"> <li><input type="checkbox"/> Age &gt;75 years</li> <li><input type="checkbox"/> History of DVT/PE</li> <li><input type="checkbox"/> <b>Family history of thrombosis*</b></li> <li><input type="checkbox"/> Positive factor V Leiden</li> <li><input type="checkbox"/> Positive prothrombin 20210A</li> <li><input type="checkbox"/> Elevated serum homocysteine</li> <li><input type="checkbox"/> Positive lupus anticoagulant</li> <li><input type="checkbox"/> Elevated anti-cardiolipin antibodies</li> <li><input type="checkbox"/> Heparin-induced thrombocytopenia</li> <li><input type="checkbox"/> Other congenital or acquired thrombophilia</li> </ul> <p>If yes: Type: _____</p> <p style="font-size: small;">*Most frequently missed risk factor</p>
---	--

  

<p style="text-align: center; background-color: #333; color: white; margin: 0;">Each Risk Factor Represents 5 Points</p> <ul style="list-style-type: none"> <li><input type="checkbox"/> Elective major lower extremity arthroplasty</li> <li><input type="checkbox"/> Hip, pelvis, or leg fracture (&lt;1 month)</li> <li><input type="checkbox"/> Stroke (&lt;1 month)</li> <li><input type="checkbox"/> Multiple trauma (&lt;1 month)</li> <li><input type="checkbox"/> Acute spinal cord injury (paralysis) (&lt;1 month)</li> </ul>
--

**Total Risk Factor Score** \_\_\_\_\_



**Figure 1. Caprini risk assessment tool for surgical patients.**

BMI indicates body mass index; COPD, chronic obstructive pulmonary disease; DVT, deep venous thrombosis; and PE, pulmonary embolism. Adapted from Venous Resource Center website<sup>123</sup> with permission. Copyright © 2020, Venous Resource Center, Dr Joseph A. Caprini.

Downloaded from http://ahajournals.org by on May 17, 2020

no demonstrable benefit from pharmacological prophylaxis (Caprini score 5–6: OR, 0.96 [95% CI, 0.60–1.53],  $P=0.85$ ; Caprini score 3–4: OR, 1.31 [95% CI, 0.51–3.3],  $P=0.57$ ; Caprini score 0–2: OR, 0.45 [95% CI, 0.10–2.09],  $P=0.31$ ). This same study showed that provision of pharmacological prophylaxis to all patients was associated with a significantly increased risk for bleeding (OR, 1.69 [95% CI, 1.16–2.45];  $P=0.006$ ). These findings further support consideration of patient-specific VTE risk in the pharmacological prophylaxis decision spectrum.<sup>130</sup>

The Padua Prediction Score (Padua score) (Table 2) identifies an ≈30-fold variation in VTE risk among acutely ill medical inpatients who receive no pharmacological prophylaxis. Patient cohorts whose risk varies between 0.3% and 11.8% can be identified with the Padua score.<sup>131</sup> Several meta-analyses specific to the medically ill inpatient population have demonstrated the benefit of pharmacological prophylaxis in high-risk patients. Existing meta-analyses that showed a benefit for pharmacological prophylaxis were performed in medical inpatients with high-risk characteristics but not explicitly in patients characterized as high risk with the Padua score.<sup>122,133–135</sup> Of note, the initial Padua Prediction Score article showed a statistically significant 90-day VTE risk reduction between patients with a Padua score  $\geq 4$  who did and did not receive pharmacological prophylaxis (2.2% versus 11.0%; hazard ratio, 0.13 [95% CI, 0.04–0.40];  $P<0.001$ ).<sup>131</sup> The 2012 ACCP guidelines for VTE prevention in nonsurgical patients<sup>29</sup> advocated for pharmacological prophylaxis for 6 to 21 days, until full restoration of mobility, or until discharge from the hospital in patients characterized as high risk with the Padua score. Those guidelines explicitly advocated against pharmacological prophylaxis for low-risk patients.

The ability of the 2005 Caprini score to predict 90-day VTE risk and response to prophylaxis has been examined in a large cohort ( $n=63\,548$ ) of medically ill patients. Although there was a linear increase in VTE risk with increasing Caprini score, there was no clear benefit of pharmacological prophylaxis at any Caprini risk level, including those at the highest risk level (Caprini score  $>8$ ).<sup>136</sup> As discussed, these findings are substantially different from findings in surgery patients. These differences may be the result of the notably different baseline VTE risk between highest-risk (Caprini score  $>8$ ) medical (1.8%, 124 of 7020)<sup>136</sup> and surgical (8.5%, 143 of 1677) patients.<sup>130</sup> Even among patients with cancer, who are generally acknowledged to be at higher risk for inpatient VTE, there is considerable variation in risk. There are no prospective studies of risk stratification in hospitalized patients with cancer, although 2 recent retrospective cohort studies in the United States and Canada have identified a Khorana Risk Score (Khorana score) cutoff of  $\geq 2$  for potential benefit from thromboprophylaxis.<sup>90,91</sup>

**Table 2. Padua Risk Assessment Model for Medical Patients**

Risk Factors for VTE in Hospitalized Medical Patients	Points
Active cancer	3
Previous VTE (with the exclusion of superficial vein thrombosis)	3
Reduced mobility	3
Already known thrombophilic condition	3
Recent ( $\leq 1$ mo) trauma or surgery	2
Elderly age ( $\geq 70$ y)	1
Heart or respiratory failure	1
Acute myocardial infarction or ischemic stroke	1
Acute infection or rheumatological disorder	1
Obesity (BMI $\geq 30$ kg/m <sup>2</sup> )	1
Ongoing hormonal treatment	1

BMI indicates body mass index; and VTE, venous thromboembolism.

Adapted from Barbar et al<sup>131</sup> with permission. Copyright © 2010, International Society of Thrombosis and Haemostasis. See also the MDCalc website.<sup>132</sup>

Existing guidelines acknowledge the extreme variation in VTE risk among the overall medical inpatient (0.3%–11.8%, characterized by the Padua score)<sup>131</sup> and surgical inpatient (0.7%–10.7%, characterized by the 2005 Caprini score) populations.<sup>130</sup> Other risk assessment tools include the IMPROVE score, highlighted in recent medical prophylaxis trials (Figure 2).<sup>138,139</sup> Categorizing baseline VTE risk and tailoring the prevention strategy to the patient level represents a paradigm for VTE care individualization. Use of D-dimer to stratify patients in terms of risk deserves further study, and has been used in 1 large trial.<sup>139</sup>

## Other Paradigms for Individualization of VTE Risk Reduction

Anticoagulants, when provided as pharmacological prophylaxis against VTE, are typically provided as a fixed dose or “one size fits all,” unmonitored strategy in the adult population. However, patients metabolize medications at different rates, and because differential metabolism affects both the risks and benefits of the drug, optimization of the patient’s anticoagulant dose represents another paradigm for care individualization. Studies among medical and surgical patients have shown that the majority of patients receive inadequate anticoagulation from a fixed-dose anticoagulation strategy for VTE prophylaxis.<sup>140–143</sup>

Patient-level factors can predict the rapidity of anticoagulant metabolism, making anticoagulant dose adequacy a potential target for VTE risk optimization. Patient weight and extent of surgical injury, in addition to other patient-level factors, correlate with rapidity of enoxaparin metabolism.<sup>141,142,144</sup> Studies have shown that weight-tiered or weight-based

VTE Risk Factors	Bleeding Risk Factors
<input type="checkbox"/> Previous VTE	<input type="checkbox"/> Gastroduodenal ulcer
<input type="checkbox"/> Thrombophilia	<input type="checkbox"/> Bleeding prior 3 months
<input type="checkbox"/> Lower limb paralysis	<input type="checkbox"/> Admission platelets $<50 \times 10^9$
<input type="checkbox"/> Current cancer	<input type="checkbox"/> Hepatic failure
<input type="checkbox"/> Immobilization $\geq 7$ days	<input type="checkbox"/> ICU/CCU stay
<input type="checkbox"/> ICU/CCU stay	<input type="checkbox"/> Cardiovascular catheter
<input type="checkbox"/> Age $>60$ years	<input type="checkbox"/> Rheumatic diseases
The incidence of asymptomatic VTE is $\approx 10$ times greater than the incidence of symptomatic disease.	<input type="checkbox"/> Current cancer
	Sex: Female
	Age: $<40$
	GFR: $\geq 60 \text{ mL} \cdot \text{min}^{-1} \cdot \text{m}^{-2}$

**Figure 2. IMPROVE (International Medical Prevention Registry on Venous Thromboembolism) score.**

CCU indicates cardiac care unit; GFR, glomerular filtration rate; ICU, intensive care unit; and VTE, venous thromboembolism. Adapted from the Center for Outcomes Research, University of Massachusetts Medical School website<sup>137</sup> with permission. Copyright © 2020, Center for Outcomes Research, University of Massachusetts Medical School.

enoxaparin dosing significantly increases the proportion of patients with adequate anti-factor Xa levels.<sup>144–149</sup> Pharmacist-driven real-time dose adjustment algorithms are also impactful in high-risk patients to optimize anti-factor Xa levels and to decrease symptomatic VTE.<sup>141,142,150</sup> Anticoagulant dose optimization in the setting of VTE prophylaxis is particularly important because at least 3 studies have correlated low anti-factor Xa levels with downstream symptomatic VTE<sup>141</sup> and asymptomatic DVT.<sup>151,152</sup>

Whether the direct oral anticoagulants can improve VTE prophylaxis effectiveness in medical and surgical patients requires further study. However, randomized controlled trials of orthopedic procedural prophylaxis with dabigatran, rivaroxaban, or apixaban compared with LMWH showed at least equal efficacy and less bleeding.<sup>153–155</sup> Similarly, LMWH is more effective than placebo for decreasing VTE, and rivaroxaban is noninferior to LMWH in VTE incidence to 35 days in acutely ill medical patients.<sup>156,157</sup> However, extended VTE prophylaxis benefit in medically ill patients with betrixaban compared with LMWH was not shown,<sup>138</sup> and extended prophylaxis with rivaroxaban was not associated with reduced VTE.<sup>139</sup>

## UNDERUSE OF VTE PROPHYLAXIS

Although there are many options for VTE prophylaxis and multiple guidelines supporting their use, these interventions are often underprescribed. A 2008 multinational study of 358 hospitals in 32 countries showed that the use of recommended pharmacological prophylaxis regimens was low.<sup>105</sup> Although 51.8% of hospitalized patients were considered to be at risk for VTE by the risk assessment model promoted in the ACCP 2004 guidelines on VTE prevention,<sup>158</sup> only 50.2% of those at-risk patients had orders for pharmacological

prophylaxis. Of those patients who were deemed at too substantial a risk for bleeding to receive anticoagulant prophylaxis, few patients were prescribed mechanical prophylaxis. In contrast, patients who were considered low risk for VTE tended to be “overprophylaxed,” with about one-third of both low-risk surgical and medical patients receiving prophylaxis that was not indicated by risk factor assessment.

A retrospective observational study of Canadian hospitals showed that fewer than one-quarter of acutely ill medical patients were prescribed any form of VTE prophylaxis, despite the fact that 90% of them had indications for it.<sup>47</sup> US hospitals performed no better, with only 12.7% of medical patients and 16.4% of surgical patients prescribed appropriate prophylaxis according to accepted guidelines.<sup>159</sup>

Even patients with cancer, who are at particularly high risk for VTE, often are prescribed inadequate prophylaxis. A study of hospital discharge information for  $>70\,000$  patients with cancer admitted for  $\geq 6$  days, of whom 58% were medical patients, showed that only 53.6% were prescribed prophylaxis. Only 27% were prescribed appropriate VTE prophylaxis as recommended by evidence-based guidelines.<sup>160</sup>

Recent data show increasing rates of prescribed prophylaxis. A consortium of hospitals in Michigan examined 44 775 medical patients admitted to non-intensive care unit floors for  $>2$  days and risk-stratified them according to the Padua Prediction Score. The authors found much high rates of prophylaxis, with 78.0% of patients deemed at high risk for VTE having orders for some form of prophylaxis.<sup>161</sup> The authors also found high rates of inappropriate prophylaxis orders, with 77.9% of low-risk medical patients prescribed excess prophylaxis, defined as the use of pharmacological prophylaxis, mechanical prophylaxis, or both, suggesting the indiscriminate use of prophylaxis.



## INTERVENTIONS TO INCREASE VTE RISK ASSESSMENT AND THROMBOPROPHYLAXIS

VTE prevention is a key element in reducing VTE-related mortality and morbidity in hospitalized medical and surgical patients. Data on rates of use of VTE risk assessment models are sparse. However, a recent study suggests that, when used consistently, VTE risk assessment models may reduce rates of prophylaxis without adversely affecting rates of VTE. Researchers compared retrospective data for patients admitted to 1 hospital before the introduction and widespread adoption of VTE risk assessment models (the Padua and IMPROVE VTE risk scores) with prospective data for patients admitted after the introduction of risk assessment models. Results for 413 patients demonstrated no significant difference in rates of PE or major bleeding. Only 43.3% of prospective patients had pharmacological prophylaxis ordered compared with 56.7% in the retrospective group.<sup>162</sup> The authors showed that risk-based assessment led to reduced healthcare expenditures from appropriate pharmacological prophylaxis, with no detriment to patient safety.

In an attempt to improve the adequate prescription of VTE thromboprophylaxis in hospitalized patients, the efficacy and safety of various types of passive and active system-wide interventions have been assessed in different hospital settings all over the world.<sup>163–166</sup> Although passive interventions such as continuing education, dissemination of guidelines, audit, and feedback were found to be insufficient, active mandatory interventions such as alerts (computer or human) appeared to be successful at improving rates of VTE prophylaxis in clinical practice. This conclusion was supported by the most recent updated Cochrane review that improved on prior meta-analyses conducted in this area in that it included a large number of participants (13 randomized controlled trials;  $n=35\,997$  participants) and was restricted to studies with randomized designs, yielding less widely differing estimates (ie, heterogeneity) across studies, more precision of the estimates of effect (ie, narrower CIs), and overall higher levels of evidence.<sup>167</sup>

Early studies on computerized alerts predate many modern electronic medical records and could be performed only on systems with integrated databases. Kucher and colleagues<sup>168</sup> reported 2506 medical and surgical patients at high risk for VTE who were receiving no VTE prophylaxis, with the responsible physician randomly alerted or not to the patient's VTE risk level. Alerted providers were also linked to the hospital's VTE prevention guidelines with the option to order prophylaxis. Patients whose providers were alerted were significantly more likely to receive mechanical (10.0% versus 1.5%;  $P<0.001$ ) and pharmacological (23.6% versus 13.0%;  $P<0.001$ ) prophylaxis, and the computer alert

reduced 90-day VTE risk by 41% (hazard ratio, 0.59 [95% CI, 0.43–0.81];  $P=0.001$ ).<sup>168</sup> This important study identified the importance of clinical decision support systems (CDSS).

Johns Hopkins implemented a service-specific and mandatory VTE decision support tool into its online order entry system. A pre/post analysis in 1599 patients undergoing trauma surgery showed that CDSS implementation significantly increased provision of guideline-adherent VTE prophylaxis (66.2% versus 84.4%;  $P<0.001$ ). Perhaps more important, the rate of preventable harm from VTE decreased significantly after CDSS implementation (1.0% versus 0.17%;  $P=0.04$ ).<sup>169</sup> In a separate analysis, the same group identified that, at baseline, there were sex and racial disparities in the provision of appropriate VTE prophylaxis for both the internal medicine and trauma surgery populations. Implementation of a CDSS significantly improved provision of compliant VTE prophylaxis and eliminated disparities in provision.<sup>170</sup> The Johns Hopkins model was subsequently implemented at the University of Virginia as a mandatory CDSS embedded into the online order entry system for patients undergoing general surgery. Implementation of the CDSS was associated with a significant decrease in 30-day VTE (1.25% versus 0.64%;  $P=0.033$ ) and allowed the institution to improve its ranking for VTE from the ninth to first decile among 760 hospitals participating in the National Surgical Quality Improvement Program.<sup>171</sup>

Boston University implemented risk stratification into its online order entry system for inpatient general and vascular surgery patients on the basis of National Surgical Quality Improvement Program data showing that its hospital was a high outlier for VTE. Individualized VTE risk stratification was mandatory, and providers received an automated suggestion about appropriate prophylaxis type and duration based on calculated Caprini score. Compliance with recommended prophylaxis regimens was high for patients at low to moderate VTE risk (100%) and for patients at high risk for VTE (89%). At the institutional level, mandatory risk stratification significantly decreased rates of DVT from 1.9% to 0.3% and PE from 1.1% to 0.5%, again highlighting that there are patient- and hospital-level benefits from CDSS implementation.<sup>172</sup>

Unfortunately, many patients prescribed thromboprophylaxis may not receive it. For instance, a study of >10 000 patient hospital stays showed that 11.9% of prescribed pharmacological prophylaxis doses were not administered.<sup>173</sup> Patients missing >1 dose of prophylaxis accounted for ≈80% of unadministered doses. A prospective trial in trauma patients found that interrupted VTE prophylaxis was associated with 5-fold increased DVT incidence.<sup>174</sup> Another study examining this issue found that patient refusal accounted for 39% of missed LMWH doses and 44% of missed unfractionated

heparin doses,<sup>175</sup> suggesting that improved patient education efforts could potentially improve patient acceptance and rates of administered prophylaxis. However, subcutaneous anticoagulant doses are more often missed than other scheduled medications<sup>176</sup> such as orally administered medications.<sup>177</sup> Thus, whether oral agents may be associated with improved VTE prophylaxis compliance bears further study. Improving patient engagement by directed education for VTE prophylaxis compliance has been proven effective.<sup>178,179</sup>

The use of payment incentives to reward increased quality of health care, so-called pay for performance, has been advocated as a means of encouraging more widespread ordering of thromboprophylaxis. For example, a hospital group created provider-level dashboards that showed individual physicians' prophylaxis orders over a period of 6 months, followed by a pay-for-performance program that gave graduated payments for the highest rates of prophylaxis orders. Researchers found that providers' rates of ordering prophylaxis increased from a baseline of 86% to as high as 94% with a combination of the dashboard and pay-for-performance measures.<sup>180</sup> A project aimed specifically at residents using pay for performance achieved even higher results, with increases in VTE prophylaxis from 89.7% to 100% over 12 months.<sup>181</sup>

In summary, alert interventions (computer or human) and multifaceted interventions included in clinicians' workflow were the most effective system-wide interventions that helped healthcare providers improve the use of appropriate VTE prophylaxis and thereby reduce the morbidity and mortality of VTE in hospitalized patients. The adoption of specific hospital system-wide measures is therefore a key element in improving the prevention of VTE in hospitalized patients.

## TRACKING OF NATIONAL VTE OUTCOMES

Accurate national documentation of VTE risk stratification, risk-appropriate application of VTE prophylaxis, and quantification of rates of VTE outcomes is possible but is currently challenging for several reasons. Although many hospitals use a procedural or quality improvement registry to improve care (and to be compliant with merit-based incentive payment system), this is neither uniform across the United States nor mandated by payers or quality improvement bodies.

National VTE measures have been developed to address the gaps in VTE thromboprophylaxis and include initiatives from the Agency for Healthcare Research and Quality, Centers for Disease Control and Prevention, and The Joint Commission.<sup>182</sup> The Agency for Healthcare Research and Quality developed its set of patient safety indicators to screen for hospital-associated

adverse events in the early 2000s.<sup>183</sup> Patient safety indicator 12, postoperative VTE, is considered a preventable hospital-acquired condition. Similarly, The Joint Commission and the National Quality Forum joined together to develop standards for the prevention of VTE and care of patients with VTE. The groups created 6 VTE core measures aligned with Centers for Medicare & Medicaid Services, which were endorsed by the National Quality Forum in 2008. The 3 measures still in use are VTE-1, which examines whether patients admitted to the hospital are prescribed thromboprophylaxis; VTE-2, which looks specifically at patients in the intensive care unit; and VTE-6, which reports the rate of hospital-acquired VTE.<sup>184</sup> The Centers for Medicare & Medicaid Services also require hospitals to report Surgical Care Improvement Project measures related to VTE, specifically the number of patients for whom prophylaxis is ordered at surgery and the number of patients who receive at least 1 dose of prophylaxis within 24 hours before or after surgery. The current Centers for Medicare & Medicaid Services ruling to have VTE be a never event in total knee or hip arthroplasty<sup>185</sup> has been criticized because it does not reflect quality of care.<sup>186</sup> For example, a recent report highlights that more than half of symptomatic VTE occurred despite optimal audited pharmacological prophylaxis.<sup>187,188</sup> It is unclear whether these penalties will continue or will be broadened to include other illnesses or surgical procedures.

The penetrance of uniform definitions of VTE and objective determination of VTE occurrence is unclear. For example, National Quality Forum measure No. 23 tracks prescription of VTE prophylaxis administration, whereas the Agency for Healthcare Research and Quality patient safety indicators include only overall VTE outcomes.<sup>189</sup> A prototypical surgical quality registry is the American College of Surgeons National Surgical Quality Improvement Program.<sup>98,100,104</sup> This has objective VTE definitions and tracks VTE occurrence to 30 days via trained nurse abstractors. It is limited because this registry does not track prescription of prophylaxis, is voluntary, and involves a modest cost; in addition, data on patients who may have a VTE after 30 days are not captured.<sup>188</sup> Furthermore, the National Surgical Quality Improvement Program does not provide variables to allow a Caprini score to be generated. Ideally, tracking VTE rates to 90 days after intervention or after hospitalization is ideal because the risk of VTE remains elevated through that time frame.<sup>8,10,96</sup>

The use of *International Classification of Diseases, 10th Revision*, codes compared with ninth revision codes might allow increased granularity and tracking of VTE rates going forward. For example, *International Classification of Diseases, Ninth Revision, Clinical Modification*, includes ≈10 codes for VTE. The 10th edition codes for VTE exceed 30, with specific capture of location and laterality of DVT, information that was not

included with *International Classification of Diseases, Ninth Revision, Clinical Modification*. This may provide a new benchmark and a way to more specifically track incident VTE rates at each hospital. However, the limits and pitfalls of administrative data such as coding errors, preexisting conditions, and lack of objective clinical definitions remain.

Another potential for improving risk assessment and prophylaxis prescription is statewide and regional quality collaboratives. For example, in the state of Michigan, quality improvement registries exist that include almost all major hospitals, including a hospital medicine registry and several surgical registries. Published studies from these registries have highlighted VTE rates, risk stratification, and prospectively defined prophylaxis use, as well as prescription of VTE prophylaxis of >75%.<sup>136,190,191</sup> However, registries are costly to run, and hospital participation is voluntary.

Lastly, these measures and potential new approaches still need to address VTE that occurs despite adequate prophylaxis, to assess whether prescribed VTE prophylaxis was actually administered, and to account for whether patients received continuous prophylaxis during their hospital stays.<sup>189</sup> A recent statewide quality effort documented that ≈18% of patients failed to receive pharmacoprophylaxis, primarily because medications were not ordered or because of patient refusal.<sup>192</sup> This study underscored a tracking system for issues with prophylaxis that is more comprehensive than many current measures. Indeed, nursing interventions, patient education, and pharmacist-led initiatives aimed at reducing missed doses and addressing patient refusal also may help.<sup>193,194</sup>

## PROPOSED POLICY STEPS TO DECREASE VTE IN HOSPITALIZED PATIENTS BY 20% BY 2030

The International Society on Thrombosis and Haemostasis has recently put forward a call for risk assessment in all hospitalized patients, similar to our document and as highlighted by World Thrombosis Day.<sup>195</sup> Much like this document, the emphasis is on the process measure of VTE risk assessment rather than an institution's VTE rate as a marker of quality and affecting care. We further support national tracking of VTE incidence to assess time trends as diagnostic testing, screening, and treatment algorithms evolve and enduring programs for public awareness to improve symptom recognition, medication adherence, and patient/family support and education.

Lau et al<sup>189</sup> nicely summarized the ideal state for VTE prevention: standardized assessment of risk, provision of risk-appropriate VTE prophylaxis, prevention of missed chemoprophylaxis doses, and definition and

**Table 3. Areas of Further Research to Inform Policy Development and Clinical Guidance**

Determine what should constitute preventable VTE across medical and surgical patients.
Compare chart-abstracted VTE rates with ICD-10 code rates in all US hospitals to assess precision and completeness.
Evaluate EMRs as a system to automatically provide risk assessment and suggest an appropriate level of VTE prophylaxis.
Define the effect of surveillance bias on VTE rates; consider a study of indications and triggers for VTE diagnostic studies and potential standardization of these across clinicians and hospitals/institutions.
Evaluate the best methods to disseminate VTE risk assessment and prophylaxis education to practitioners and VTE risks to patients and families.
Compare the VTE risk scoring prospectively against specific pharmacological and mechanical prophylaxis.
Evaluate and test best methods to prevent missed prophylaxis dosing and to improve compliance.

EMR indicates electronic medical record; ICD-10, *International Classification of Diseases, 10th Revision*; and VTE, venous thromboembolism.

tracking of rates of preventable VTE. Preventable VTE is defined as occurring in a high-risk patient not prescribed adequate VTE prophylaxis, whereas nonpreventable VTE occurs in those who have received appropriate risk assessment and thromboprophylaxis with documentation of compliance. Objectively determined VTE is defined as a clinically manifest VTE, confirmed with standard imaging. Many areas, however, require further study and further research to provide evidence for practice and policy (Table 3).

Given the current state of nonuniform individualized risk assessment and the overuse and underuse of VTE prophylaxis in low- and high-risk patients, respectively, we believe the evidence and tools are now available to allow several VTE prevention goals to be accomplished, in part through the government and payer policies listed below.

- The AHA supports performing VTE risk assessment and reporting the level of VTE risk in all hospitalized patients.
- The AHA supports the use of the indicator preventable VTE as a benchmark for hospital comparison and pay-for-performance programs (eg, Medicaid, Medicare).
- The AHA supports appropriations for collaborative initiatives across public health, clinical practice, and private sectors to improve public awareness of VTE.
- The AHA supports national tracking of objectively determined VTE with the use of standardized definitions of VTE that occurs within 90 days of a hospital stay.
- The AHA recommends a central steward for data tracking VTE risk assessment, application of VTE prophylaxis, and VTE rates for all hospitals such as the Core Quality Measures Collaborative.<sup>196</sup>

## ARTICLE INFORMATION

The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.

This statement was approved by the American Heart Association Advocacy Coordinating Committee on November 22, 2019, and the American Heart Association Executive Committee on December 10, 2019. A copy of the document is available at <https://professional.heart.org/statements> by using either "Search for Guidelines & Statements" or the "Browse by Topic" area. To purchase additional reprints, call 215-356-2721 or email Meredith.Edelman@wolterskluwer.com.

The American Heart Association requests that this document be cited as follows: Henke PK, Kahn SR, Pannucci CJ, Secemsky EA, Evans NS, Khorana

AA, Creager MA, Pradhan AD; on behalf of the American Heart Association Advocacy Coordinating Committee. Call to action to prevent venous thromboembolism in hospitalized patients: a policy statement from the American Heart Association. *Circulation*. 2020;141:e000–e000. doi: 10.1161/CIR.0000000000000769

The expert peer review of AHA-commissioned documents (eg, scientific statements, clinical practice guidelines, systematic reviews) is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines development, visit <https://professional.heart.org/statements>. Select the "Guidelines & Statements" drop-down menu, then click "Publication Development."

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at <https://www.heart.org/permissions>. A link to the "Copyright Permissions Request Form" appears in the second paragraph (<https://www.heart.org/en/about-us/statements-and-policies/copyright-request-form>).

## Disclosures

### Writing Group Disclosures

Writing Group Member	Employment	Research Grant	Other Research Support	Speakers' Bureau/Honoraria	Expert Witness	Ownership Interest	Consultant/Advisory Board	Other
Peter K. Henke	University of Michigan	None	None	None	None	None	None	None
Mark A. Creager	Dartmouth Hitchcock Medical Center	None	None	None	None	None	None	None
Natalie S. Evans	Cleveland Clinic	None	None	None	None	None	None	None
Susan R. Kahn	McGill University	CIHR and multiple nonprofit and for-profit funding partner†; Tier 1 Canada Research Chair in Venous Thromboembolism†; investigator of the CanVECTOR Network (funded by Canadian Institutes of Health Research CDT-142654)*	None	None	None	None	Advisory Board for Pfizer*; Sanofi*; Servier*	None
Alok A. Khorana	Cleveland Clinic	Array*; BMS*; Leap*; Merck*; research support from the Sondra and Stephen Hardis Chair in Oncology Research†; National Heart, Lung, and Blood Institute (U01HL143402, R34 HL127156)†	None	None	None	None	Bayert; Halozyme*; Janssen†; Pfizer*; Pharmacytics*; Pharmocyte*; Sanofi†; Seattle Genetics*; Trisalus*	None
Christopher J. Pannucci	University of Utah	None	None	None	Provided expert opinion on the defense side for a case of fatal postoperative pulmonary embolus (2018)*	None	None	None
Aruna D. Pradhan	Brigham and Women's Hospital	None	None	None	None	None	None	None
Eric A. Secemsky	Beth Israel Hospital	None	None	None	None	None	None	None

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be "significant" if (a) the person receives \$10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns \$10 000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition.

\*Modest.

†Significant.

## Reviewer Disclosures

Reviewer	Employment	Research Grant	Other Research Support	Speakers' Bureau/Honoraria	Expert Witness	Ownership Interest	Consultant/Advisory Board	Other
Elliott R. Haut	Johns Hopkins University	Agency for Healthcare Research and Quality (PI of R01 research grant)†; National Heart, Lung, and Blood Institute (Co-I of R21 research grant)†	Patient-Centered Outcomes Research Institute (PI and Co-I of numerous PCORI-funded projects)†	None	None	None	None	None
Scott Kaatz	Henry Ford Hospital	Janssen (research funds to my institution; I was the site PI)*	None	None	None	None	Janssen†; Pfizer†; Portola*; Roche*	None
Gary Raskob	University of Oklahoma	CDC (VTE surveillance)†	None	None	None	None	Janssen†; Bayer†; Daiichi Sankyo†; Portola†; BMS*; Pfizer*; Tetherex*	None
Jeffrey I. Weitz	Thrombosis & Atherosclerosis Research Institute (Canada)	None	None	None	None	None	None	None

This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be "significant" if (a) the person receives \$10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns \$10 000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition.

\*Modest.

†Significant.

## REFERENCES

- International Society on Thrombosis and Haemostasis Steering Committee for World Thrombosis. Thrombosis: a major contributor to global disease burden. *J Thromb Haemost*. 2014;12:1580–1590. doi: 10.1161/ATVBAHA.114.304488
- Fernandez MM, Hogue S, Preblich R, Kwong WJ. Review of the cost of venous thromboembolism. *Clinicoecon Outcomes Res*. 2015;7:451–462. doi: 10.2147/CEOR.S85635
- Wendelboe AM, Raskob GE. Global burden of thrombosis: epidemiologic aspects. *Circ Res*. 2016;118:1340–1347. doi: 10.1161/CIRCRESAHA.115.306841
- Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. *J Thromb Thrombolysis*. 2016;41:3–14. doi: 10.1007/s11239-015-1311-6
- Maynard G. *Preventing Hospital-Associated Venous Thromboembolism: A Guide For Effective Quality Improvement*. 2nd ed. Rockville, MD: Agency for Healthcare Research and Quality; August 2016. AHRQ Publication No. 16-0001-EF.
- Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. *Am J Prev Med*. 2010;38(suppl):S495–S501. doi: 10.1016/j.amepre.2009.12.017
- Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chiuve SE, Cushman M, Delling FN, Deo R, et al; on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2018 update: a report from the American Heart Association [published correction appears in *Circulation*. 2018;147:e493]. *Circulation*. 2018;137:e67–e492. doi: 10.1161/CIR.0000000000000558
- Zakai NA, McClure LA, Judd SE, Safford MM, Folsom AR, Lutsey PL, Cushman M. Racial and regional differences in venous thromboembolism in the United States in 3 cohorts. *Circulation*. 2014;129:1502–1509. doi: 10.1161/CIRCULATIONAHA.113.006472
- Huang W, Goldberg RJ, Anderson FA, Kiefe CI, Spencer FA. Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985–2009). *Am J Med*. 2014;127:829–839.e5.
- Heit JA, Ashrani A, Crusan DJ, McBane RD, Petterson TM, Bailey KR. Reasons for the persistent incidence of venous thromboembolism. *Thromb Haemost*. 2017;117:390–400. doi: 10.1160/TH16-07-0509
- Bell EJ, Lutsey PL, Basu S, Cushman M, Heckbert SR, Lloyd-Jones DM, Folsom AR. Lifetime risk of venous thromboembolism in two cohort studies. *Am J Med*. 2016;129:339.e19–339.e26. doi: 10.1016/j.amjmed.2015.10.014
- Heit JA, Melton LJ 3rd, Lohse CM, Petterson TM, Silverstein MD, Mohr DN, O'Fallon WM. Incidence of venous thromboembolism in hospitalized patients vs community residents. *Mayo Clin Proc*. 2001;76:1102–1110. doi: 10.4065/76.11.1102
- Heit JA, O'Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, Melton LJ 3rd. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. *Arch Intern Med*. 2002;162:1245–1248. doi: 10.1001/archinte.162.11.1245
- Noboa S, Mottier D, Oger E; EPI-GETBO Study Group. Estimation of a potentially preventable fraction of venous thromboembolism: a community-based prospective study. *J Thromb Haemost*. 2006;4:2720–2722. doi: 10.1111/j.1538-7836.2006.02196.x
- Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ. Venous thromboembolism in the outpatient setting. *Arch Intern Med*. 2007;167:1471–1475. doi: 10.1001/archinte.167.14.1471
- Anderson FA Jr, Zayaruzny M, Heit JA, Fidan D, Cohen AT. Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. *Am J Hematol*. 2007;82:777–782. doi: 10.1002/ajh.20983
- Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). *Chest*. 2008;133(suppl):381S–453S. doi: 10.1378/chest.08-0656
- Bozzato S, Galli L, Ageno W. Thromboprophylaxis in surgical and medical patients. *Semin Respir Crit Care Med*. 2012;33:163–175. doi: 10.1055/s-0032-1311795
- Streiff MB, Lau BD. Thromboprophylaxis in nonsurgical patients. *Hematol Am Soc Hematol Educ Program*. 2012;2012:631–637. doi: 10.1182/asheducation-2012.1.631
- Bozarth AL, Bajaj N, Abdeljalil A. A review of venous thromboembolism prophylaxis for hospitalized medical patients. *Hosp Pract (1995)*. 2013;41:60–69. doi: 10.3810/hp.2013.08.1069

21. Shirvanian S, Tapson VF. Venous thromboembolism: identifying patients at risk and establishing prophylaxis. *Curr Med Res Opin.* 2015;31:2297–2311. doi: 10.1185/03007995.2015.1098599
22. Hansrani V, Khanbhai M, McCollum C. The prevention of venous thromboembolism in surgical patients. *Adv Exp Med Biol.* 2017;906:1–8. doi: 10.1007/5584\_2016\_100
23. Geerts W. Antithrombotic and thrombolytic therapy. *Chest.* 2008;133:381s–451s.
24. Qaseem A, Chou R, Humphrey LL, Starkey M, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline from the American College of Physicians. *Ann Intern Med.* 2011;155:625–632. doi: 10.7326/0003-4819-155-9-201111010-00011
25. Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, Ortel TL, Pauker SG, Colwell CW Jr. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* 2012;141(suppl):e278S–e325S. doi: 10.1378/chest.11-2404
26. Gould MK, Garcia DA, Wren SM, Karanickolas PJ, Arcelus JI, Heit JA, Samama CM; American College of Chest Physicians. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* 2012;141(suppl):e227S–e277S. doi: 10.1378/chest.11-2297
27. Jacobs JJ, Mont MA, Bozic KJ, Della Valle CJ, Goodman SB, Lewis CG, Yates AC Jr, Boggio LN, Watters WC 3rd, Turkelson CM, et al. American Academy of Orthopaedic Surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. *J Bone Joint Surg Am.* 2012;94:746–747. doi: 10.2106/JBJS.9408.ebo746
28. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Balekian AA, Klein RC, Le H, et al; American College of Chest Physicians. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* 2012;141(suppl):e195S–e226S. doi: 10.1378/chest.11-2296
29. Nicolaidis AN, Fareed J, Kakkar AK, Comerota AJ, Goldhaber SZ, Hull R, Myers K, Samama M, Fletcher J, Kalodiki E, et al. Prevention and treatment of venous thromboembolism: international consensus statement. *Int Angiol.* 2013;32:111–260.
30. Farge D, Bounameaux H, Brenner B, Cajfinger F, Debourdeau P, Khorana AA, Pabinger I, Solymoss S, Douketis J, Kakkar A. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. *Lancet Oncol.* 2016;17:e452–e466. doi: 10.1016/S1470-2045(16)30369-2
31. Liew NC, Alemany GV, Angchaisuksiri P, Bang SM, Choi G, De Silva DA, Hong JM, Lee L, Li YJ, Rajamoney GN, et al. Asian venous thromboembolism guidelines: updated recommendations for the prevention of venous thromboembolism. *Int Angiol.* 2017;36:1–20. doi: 10.23736/S0392-9590.16.03765-2
32. National Institute for Health and Care Excellence. NICE guidelines: venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. 2018. <https://www.nice.org.uk/guidance/ng89/chapter/Recommendations>. Accessed September 5, 2018.
33. Schünemann HJ, Cushman M, Burnett AE, Kahn SR, Beyer-Westendorf J, Spencer FA, Rezende SM, Zakai NA, Bauer KA, Dentali F, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. *Blood Adv.* 2018;2:3198–3225. doi: 10.1182/bloodadvances.2018022954
34. Randelli F, Cimminiello C, Capozzi M, Bosco M, Cerulli G; GIOTTO Investigators. Real life thromboprophylaxis in orthopedic surgery in Italy: results of the GIOTTO study. *Thromb Res.* 2016;137:103–107. doi: 10.1016/j.thromres.2015.11.007
35. Kim PS, Gasparis AP, Probeck K, Elitharp D, Tassiopoulos A, Labropoulos N. Accuracy of venous thromboembolism assessment and compliance to prophylaxis in a tertiary care center. *Phlebology.* 2016;31:541–545. doi: 10.1177/0268355515604758
36. Hibbert PD, Hannaford NA, Hooper TD, Hindmarsh DM, Braithwaite J, Ramanathan SA, Wickham N, Runciman WB. Assessing the appropriateness of prevention and management of venous thromboembolism in Australia: a cross-sectional study. *BMJ Open.* 2016;6:e008618. doi: 10.1136/bmjopen-2015-008618
37. Geachan N, Basile M, Tohmeh M; DIONYS Registry. Venous thromboembolism prophylaxis in patients undergoing abdominal and pelvic cancer surgery: adherence and compliance to ACCP guidelines in DIONYS Registry. *Springerplus.* 2016;5:1541. doi: 10.1186/s40064-016-3057-9
38. Farfan M, Bautista M, Bonilla G, Rojas J, Linás A, Navas J. Worldwide adherence to ACCP guidelines for thromboprophylaxis after major orthopedic surgery: a systematic review of the literature and meta-analysis. *Thromb Res.* 2016;141:163–170. doi: 10.1016/j.thromres.2016.03.029
39. Akinbobuyi O, Shalders L, Nokes T. Ensuring timely thromboprophylaxis on a medical assessment unit. *BMJ Qual Improv Rep.* 2016;5:u212414.
40. Vazquez F, Watman R, Tabares A, Gumpel C, Baldessari E, Vilaseca AB, Capparelli FJ, Lifschitz E. Risk of venous thromboembolic disease and adequacy of prophylaxis in hospitalized patients in Argentina: a multicentric cross-sectional study. *Thromb J.* 2014;12:15. doi: 10.1186/1477-9560-12-15
41. Al-Hameed F, Al-Dorzi HM, Aboelnazer E. The effect of a continuing medical education program on venous thromboembolism prophylaxis utilization and mortality in a tertiary-care hospital. *Thromb J.* 2014;12:9. doi: 10.1186/1477-9560-12-9
42. Adamali H, Suliman AM, Zaid H, O'Donoghue E, Burke A, Suliman AW, Salem M, O'Toole A, Yearoo AI, Javid S, et al; PREVENT VTE Investigators. A national house-staff audit of medical prophylaxis in medical patients for the PREVENTion of Venous ThromboEmbolism (PREVENT-VTE). *Ir Med J.* 2013;106:302–305.
43. Stein PD, Matta F, Dalen JE. Is the campaign to prevent VTE in hospitalized patients working? *Chest.* 2011;139:1317–1321. doi: 10.1378/chest.10-1622
44. Schleyer AM, Schreuder AB, Jarman KM, Logerfo JP, Goss JR. Adherence to guideline-directed venous thromboembolism prophylaxis among medical and surgical inpatients at 33 academic medical centers in the United States. *Am J Med Qual.* 2011;26:174–180. doi: 10.1177/1062860610382289
45. Khoury H, Welner S, Kubin S, Folkerts K, Haas S. Disease burden and unmet needs for prevention of venous thromboembolism in medically ill patients in Europe show underutilization of preventive therapies. *Thromb Haemost.* 2011;106:600–608. doi: 10.1160/TH11-03-0168
46. Dobesh P. The importance of appropriate prophylaxis for the prevention of venous thromboembolism in at-risk medical patients. *Int J Clin Pract.* 2010;64:1554–1562. doi: 10.1111/j.1742-1241.2010.02447.x
47. Kahn SR, Panju A, Geerts W, Pineo GF, Desjardins L, Turpie AG, Glezer S, Thabane L, Sebaldt RJ; CURVE Study Investigators. Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. *Thromb Res.* 2007;119:145–155. doi: 10.1016/j.thromres.2006.01.011
48. Alotaibi GS, Wu C, Senthilselvan A, McMurtry MS. Secular trends in incidence and mortality of acute venous thromboembolism: the AB-VTE population-based study. *Am J Med.* 2016;129:879.e19–879.e25. doi: 10.1016/j.amjmed.2016.01.041
49. Jiménez D, de Miguel-Díez J, Guíjarro R, Trujillo-Santos J, Otero R, Barba R, Muriel A, Meyer G, Yusen RD, Monreal M; RIETE Investigators. Trends in the management and outcomes of acute pulmonary embolism: analysis from the RIETE Registry. *J Am Coll Cardiol.* 2016;67:162–170. doi: 10.1016/j.jacc.2015.10.060
50. Bikdeli B, Wang Y, Minges KE, Desai NR. Hospitalizations, therapies, and outcomes of pulmonary embolism in Medicare beneficiaries: trends are similar to Europe. *J Am Coll Cardiol.* 2016;67:2559–2560. doi: 10.1016/j.jacc.2016.02.075
51. Minges KE, Bikdeli B, Wang Y, Kim N, Curtis JP, Desai MM, Krumholz HM. National trends in pulmonary embolism hospitalization rates and outcomes for adults aged ≥65 years in the United States (1999 to 2010). *Am J Cardiol.* 2015;116:1436–1442. doi: 10.1016/j.amjcard.2015.07.068
52. de Miguel-Díez J, Jiménez-García R, Jiménez D, Monreal M, Guíjarro R, Otero R, Hernández-Barrera V, Trujillo-Santos J, López de Andrés A, Carrasco-Garrido P. Trends in hospital admissions for pulmonary embolism in Spain from 2002 to 2011. *Eur Respir J.* 2014;44:942–950. doi: 10.1183/09031936.00194213
53. Tsai J, Grosse SD, Grant AM, Hooper WC, Atrash HK. Trends in in-hospital deaths among hospitalizations with pulmonary embolism. *Arch Intern Med.* 2012;172:960–961. doi: 10.1001/archinternmed.2012.198
54. Stein PD, Matta F, Alrifai A, Rahman A. Trends in case fatality rate in pulmonary embolism according to stability and treatment. *Thromb Res.* 2012;130:841–846. doi: 10.1016/j.thromres.2012.07.011
55. Wendelboe AM, McCumber M, Hylek EM, Buller H, Weitz JI, Raskob G; ISTH Steering Committee for World Thrombosis Day. Global public awareness of venous thromboembolism. *J Thromb Haemost.* 2015;13:1365–1371. doi: 10.1111/jth.13031

56. Shekelle PG, Pronovost PJ, Wachtel RM, McDonald KM, Schoelles K, Dy SM, Shojania K, Reston JT, Adams AS, Angood PB, et al. The top patient safety strategies that can be encouraged for adoption now. *Ann Intern Med.* 2013;158(pt 2):365–368. doi: 10.7326/0003-4819-158-5-201303051-00001
57. Secemsky EA, Rosenfield K, Kennedy KF, Jaff M, Yeh RW. High burden of 30-day readmissions after acute venous thromboembolism in the United States. *J Am Heart Assoc.* 2018;7:e009047. doi: 10.1161/JAHA.118.009047
58. Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous thrombosis. *Lancet.* 2010;376:2032–2039. doi: 10.1016/S0140-6736(10)60962-2
59. Grosse SD. Cost-of-illness models for venous thromboembolism: one size does not fit all. *Thromb Res.* 2016;145:65–66. doi: 10.1016/j.thromres.2016.07.018
60. Prandoni P, Kahn SR. Post-thrombotic syndrome: prevalence, prognostication and need for progress. *Br J Haematol.* 2009;145:286–295. doi: 10.1111/j.1365-2141.2009.07601.x
61. Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, Albanese P, Biasiolo A, Pegoraro C, Illiceto S, et al; Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. *N Engl J Med.* 2004;350:2257–2264. doi: 10.1056/NEJMoa032274
62. Raja AS, Greenberg JO, Qaseem A, Denberg TD, Fitterman N, Schuur JD; Clinical Guidelines Committee of the American College of Physicians. Evaluation of patients with suspected acute pulmonary embolism: best practice advice from the Clinical Guidelines Committee of the American College of Physicians. *Ann Intern Med.* 2015;163:701–711. doi: 10.7326/M14-1772
63. Geersing GJ, Erkens PM, Lucassen WA, Büller HR, Cate HT, Hoes AW, Moons KG, Prins MH, Oudegra R, van Weert HC, et al. Safe exclusion of pulmonary embolism using the Wells rule and qualitative D-dimer testing in primary care: prospective cohort study. *BMJ.* 2012;345:e6564. doi: 10.1136/bmj.e6564
64. Lucassen W, Geersing GJ, Erkens PM, Reitsma JB, Moons KG, Büller H, van Weert HC. Clinical decision rules for excluding pulmonary embolism: a meta-analysis. *Ann Intern Med.* 2011;155:448–460. doi: 10.7326/0003-4819-155-7-201110040-00007
65. Le Gal G, Righini M. Controversies in the diagnosis of venous thromboembolism. *J Thromb Haemost.* 2015;13(suppl 1):S259–S265. doi: 10.1111/jth.12937
66. Stein PD, Matta F. Vena cava filters in unstable elderly patients with acute pulmonary embolism. *Am J Med.* 2014;127:222–225. doi: 10.1016/j.amjmed.2013.11.003
67. Stein PD, Matta F. Thrombolytic therapy in unstable patients with acute pulmonary embolism: saves lives but underused. *Am J Med.* 2012;125:465–470. doi: 10.1016/j.amjmed.2011.10.015
68. Haut ER, Pronovost PJ. Surveillance bias in outcomes reporting. *JAMA.* 2011;305:2462–2463. doi: 10.1001/jama.2011.822
69. Haut ER, Noll K, Efron DT, Berenholz SM, Haider A, Cornwell EE 3rd, Pronovost PJ. Can increased incidence of deep vein thrombosis (DVT) be used as a marker of quality of care in the absence of standardized screening? The potential effect of surveillance bias on reported DVT rates after trauma. *J Trauma.* 2007;63:1132–1135. doi: 10.1097/TA.0b013e31814856ad
70. Bilimoria KY, Chung J, Ju MH, Haut ER, Bentrem DJ, Ko CY, Baker DW. Evaluation of surveillance bias and the validity of the venous thromboembolism quality measure. *JAMA.* 2013;310:1482–1489. doi: 10.1001/jama.2013.280048
71. Goldhaber SZ. Risk factors for venous thromboembolism. *J Am Coll Cardiol.* 2010;56:1–7. doi: 10.1016/j.jacc.2010.01.057
72. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Olsson CG, Turpie AG; MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. *Arch Intern Med.* 2004;164:963–968. doi: 10.1001/archinte.164.9.963
73. Cohoon KP, Ashrani AA, Crusan DJ, Petterson TM, Bailey KR, Heit JA. Is infection an independent risk factor for venous thromboembolism? A population-based, case-control study. *Am J Med.* 2018;131:307–316. doi: 10.1016/j.amjmed.2017.09.015
74. Kaplan D, Casper TC, Elliott CG, Men S, Pendleton RC, Kraiss LW, Weyrich AS, Grissom CK, Zimmerman GA, Rondina MT. VTE incidence and risk factors in patients with severe sepsis and septic shock. *Chest.* 2015;148:1224–1230. doi: 10.1378/chest.15-0287
75. Rinde LB, Smabrekke B, Mathiesen EB, Lochen ML, Njolstad I, Hald EM, Wilsaard T, Braekkan SK, Hansen JB. Ischemic stroke and risk of venous thromboembolism in the general population: the Tromsø study. *J Am Heart Assoc.* 2016;5:e004311. doi: 10.1161/JAHA.116.004311
76. Kelly J, Rudd A, Lewis R, Hunt BJ. Venous thromboembolism after acute stroke. *Stroke.* 2001;32:262–267. doi: 10.1161/01.str.32.1.262
77. Tang L, Wu YY, Lip GY, Yin P, Hu Y. Heart failure and risk of venous thromboembolism: a systematic review and meta-analysis. *Lancet Haematol.* 2016;3:e30–e44. doi: 10.1016/S2352-3026(15)00228-8
78. Piazza G, Seddighzadeh A, Goldhaber SZ. Heart failure in patients with deep vein thrombosis. *Am J Cardiol.* 2008;101:1056–1059. doi: 10.1016/j.amjcard.2007.11.051
79. Ng TM, Tsai F, Khatri N, Barakat MN, Elkayam U. Venous thromboembolism in hospitalized patients with heart failure: incidence, prognosis, and prevention. *Circ Heart Fail.* 2010;3:165–173. doi: 10.1161/CIRCHEARTFAILURE.109.892349
80. Howell MD, Geraci JM, Knowlton AA. Congestive heart failure and outpatient risk of venous thromboembolism: a retrospective, case-control study. *J Clin Epidemiol.* 2001;54:810–816. doi: 10.1016/s0895-4356(00)00373-5
81. Mebazaa A, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Merli G, Schellong SW, Spyropoulos AC, Tapson VF, et al. Predicting the risk of venous thromboembolism in patients hospitalized with heart failure. *Circulation.* 2014;130:410–418. doi: 10.1161/CIRCULATIONAHA.113.003126
82. Giannotta M, Tapete G, Emmi G, Silvestri E, Milla M. Thrombosis in inflammatory bowel diseases: what's the link? *Thromb J.* 2015;13:14. doi: 10.1186/s12959-015-0044-2
83. Murthy SK, Nguyen GC. Venous thromboembolism in inflammatory bowel disease: an epidemiological review. *Am J Gastroenterol.* 2011;106:713–718. doi: 10.1038/ajg.2011.53
84. Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. *Am J Gastroenterol.* 2008;103:2272–2280. doi: 10.1111/j.1572-0241.2008.02052.x
85. Zöller B, Li X, Sundquist J, Sundquist K. Autoimmune diseases and venous thromboembolism: a review of the literature. *Am J Cardiovasc Dis.* 2012;2:171–183.
86. Borjas-Howard JF, Leeuw K, Rutgers A, Meijer K, Tichelaar VYIG. Risk of recurrent venous thromboembolism in autoimmune diseases: a systematic review of the literature. *Semin Thromb Hemost.* 2019;45:141–149. doi: 10.1055/s-0038-1661387
87. Lee JJ, Pope JE. A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases. *Arthritis Res Ther.* 2014;16:435. doi: 10.1186/s13075-014-0435-y
88. Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. *J Clin Oncol.* 2009;27:4839–4847. doi: 10.1200/JCO.2009.22.3271
89. Lyman GH, Culakova E, Poniewierski MS, Kuderer NM. Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer. *Thromb Res.* 2018;164(suppl 1):S112–S118. doi: 10.1016/j.thromres.2018.01.028
90. Parker A, Peterson E, Lee AYY, de Wit C, Carrier M, Polley G, Tien J, Wu C. Risk stratification for the development of venous thromboembolism in hospitalized patients with cancer. *J Thromb Haemost.* 2018;16:1321–1326. doi: 10.1111/jth.14139
91. Patell R, Rybicki L, McCrae KR, Khorana AA. Predicting risk of venous thromboembolism in hospitalized cancer patients: utility of a risk assessment tool. *Am J Hematol.* 2017;92:501–507. doi: 10.1002/ajh.24700
92. Burleigh E, Wang C, Foster D, Heller S, Dunn D, Safavi K, Griffin B, Smith J. Thromboprophylaxis in medically ill patients at risk for venous thromboembolism. *Am J Health Syst Pharm.* 2006;63(suppl 6):S23–S29. doi: 10.2146/ajhp060390
93. Zwicker JJ, Rojan A, Campigotto F, Rehman N, Funches R, Connolly G, Webster J, Aggarwal A, Mobarek D, Faselis C, et al. Pattern of frequent but nontargeted pharmacologic thromboprophylaxis for hospitalized patients with cancer at academic medical centers: a prospective, cross-sectional, multicenter study. *J Clin Oncol.* 2014;32:1792–1796. doi: 10.1200/JCO.2013.53.5336
94. Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, et al; CASSINI Investigators. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. *N Engl J Med.* 2019;380:720–728. doi: 10.1056/NEJMoa1814630
95. Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, Kuruvilla P, Hill D, Spadafora S, Marquis K, et al; AVERT Investigators. Apixaban to prevent venous thromboembolism in patients with cancer. *N Engl J Med.* 2019;380:711–719. doi: 10.1056/NEJMoa1814468

96. White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. *Thromb Haemost*. 2003;90:446–455. doi: 10.1160/TH03-03-0152
97. Gangireddy C, Rectenwald JR, Upchurch GR, Wakefield TW, Khuri S, Henderson WG, Henke PK. Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. *J Vasc Surg*. 2007;45:335–341. doi: 10.1016/j.jvs.2006.10.034
98. Bilimoria KY, Liu Y, Paruch JL, Zhou L, Kmieciak TE, Ko CY, Cohen ME. Development and evaluation of the universal ACS NSQIP surgical risk calculator: a decision aid and informed consent tool for patients and surgeons. *J Am Coll Surg*. 2013;217:833–42.e1. doi: 10.1016/j.jamcollsurg.2013.07.385
99. VanDluc AA, Cowan NG, Chen Y, Anderson RE, Conlin MJ, La Rochelle JC, Amling CL, Koppie TM. Timing, incidence and risk factors for venous thromboembolism in patients undergoing radical cystectomy for malignancy: a case for extended duration pharmacological prophylaxis. *J Urol*. 2014;191:943–947. doi: 10.1016/j.juro.2013.10.096
100. Merkow RP, Bilimoria KY, McCarter MD, Cohen ME, Barnett CC, Raval MV, Caprini JA, Gordon HS, Ko CY, Bentrem DJ. Post-discharge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis. *Ann Surg*. 2011;254:131–137. doi: 10.1097/SLA.0b013e31821b98da
101. Arcelus JJ, Monreal M, Caprini JA, Guisado JG, Soto MJ, Núñez MJ, Álvarez JC; RIETE Investigators. Clinical presentation and time-course of postoperative venous thromboembolism: results from the RIETE Registry. *Thromb Haemost*. 2008;99:546–551. doi: 10.1160/TH07-10-0611
102. Ramanathan R, Lee N, Duane TM, Gu Z, Nguyen N, Potter T, Rensing E, Sampson R, Burrows M, Banas C, et al. Correlation of venous thromboembolism prophylaxis and electronic medical record alerts with incidence among surgical patients. *Surgery*. 2016;160:1202–1210. doi: 10.1016/j.surg.2016.04.029
103. Ramanan B, Gupta PK, Sundaram A, Lynch TG, MacTaggart JN, Baxter BT, Johanning JM, Pipinos II. In-hospital and postdischarge venous thromboembolism after vascular surgery. *J Vasc Surg*. 2013;57:1589–1596. doi: 10.1016/j.jvs.2012.11.073
104. DeWane MP, Davis KA, Schuster KM, Maung AA, Becher RD. Venous thromboembolism-related readmission in emergency general surgery patients: a role for prophylaxis on discharge? *J Am Coll Surg*. 2018;226:1072–1077.e3. doi: 10.1016/j.jamcollsurg.2018.03.021
105. Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, Huang W, Zayaruzny M, Emery L, Anderson FA Jr; ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. *Lancet*. 2008;371:387–394. doi: 10.1016/S0140-6736(08)60202-0
106. Le Sage S, McGee M, Emed JD. Knowledge of venous thromboembolism (VTE) prevention among hospitalized patients. *J Vasc Nurs*. 2008;26:109–117. doi: 10.1016/j.jvn.2008.09.005
107. Apenteng PN, Fitzmaurice D, Litchfield I, Harrison S, Heneghan C, Ward A, Greenfield S. Patients' perceptions and experiences of the prevention of hospital-acquired thrombosis: a qualitative study. *BMJ Open*. 2016;6:e013839. doi: 10.1136/bmjopen-2016-013839
108. Almodaimegh H, Alfehaid L, Alsuehaby N, Bustami R, Alharbi S, Alkatheri A, Albekairy A. Awareness of venous thromboembolism and thromboprophylaxis among hospitalized patients: a cross-sectional study. *Thromb J*. 2017;15:19. doi: 10.1186/s12959-017-0144-2
109. Popoola VO, Lau BD, Shihab HM, Farrow NE, Shaffer DL, Hobson DB, Kulik SV, Zaruba PD, Shermock KM, Kraus PS, et al. Patient preferences for receiving education on venous thromboembolism prevention: a survey of stakeholder organizations. *PLoS One*. 2016;11:e0152084. doi: 10.1371/journal.pone.0152084
110. World Thrombosis Day website. <https://www.worldthrombosisday.org>. Accessed August 10, 2018.
111. Guyatt GH, Akl EA, Gutterman M, Schunemann HJ, Gutterman DD, Lewis SZ. Introduction to the ninth edition: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141:485–525.
112. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. *Chest*. 2016;149:315–352. doi: 10.1016/j.chest.2015.11.026
113. Lyman GH, Bohlik K, Falanga A; American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. *J Oncol Pract*. 2015;11:e442–e444. doi: 10.1200/JOP.2015.004473
114. Mont MA, Jacobs JJ. AAOS clinical practice guideline: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. *J Am Acad Orthop Surg*. 2011;19:777–778. doi: 10.5435/00124635-201112000-00008
115. Ressel GW; American College of Obstetricians and Gynecologists. ACOG practice bulletin on preventing deep venous thrombosis and pulmonary embolism. *Am Fam Physician*. 2001;63:2279–2280.
116. Rogers FB, Cipolle MD, Velmahos G, Rozycki G, Luchette FA. Practice management guidelines for the prevention of venous thromboembolism in trauma patients: the EAST Practice Management Guidelines Work Group. *J Trauma*. 2002;53:142–164. doi: 10.1097/00005373-200207000-00032
117. Shafi S, Nathens AB, Cryer HG, Hemmila MR, Pasquale MD, Clark DE, Neal M, Goble S, Meredith JW, Fildes JJ. The Trauma Quality Improvement Program of the American College of Surgeons Committee on Trauma. *J Am Coll Surg*. 2009;209:521–530.e1. doi: 10.1016/j.jamcollsurg.2009.07.001
118. Stuck AK, Spirk D, Schaudt J, Kucher N. Risk assessment models for venous thromboembolism in acutely ill medical patients: a systematic review. *Thromb Haemost*. 2017;117:801–808. doi: 10.1160/TH16-08-0631
119. Haut ER, Schneider EB, Patel A, Streiff MB, Haider AH, Stevens KA, Chang DC, Neal ML, Hoefl C, Nathens AB, et al. Duplex ultrasound screening for deep vein thrombosis in asymptomatic trauma patients: a survey of individual trauma surgeon opinions and current trauma center practices. *J Trauma*. 2011;70:27–33. doi: 10.1097/TA.0b013e3182077d55
120. Malhotra AK, Goldberg SR, McClay L, Martin NR, Wolfe LG, Levy MM, Khatani V, Borchers TC, Duane TM, Aboutanos MB, et al. DVT surveillance program in the ICU: analysis of cost-effectiveness. *PLoS One*. 2014;9:e106793. doi: 10.1371/journal.pone.0106793
121. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, et al; American Society of Clinical Oncology. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. *J Clin Oncol*. 2007;25:5490–5505. doi: 10.1200/JCO.2007.14.1283
122. Alikhan R, Bedenis R, Cohen AT. Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction). *Cochrane Database Syst Rev*. 2014;CD003747. doi: 10.1002/14651858.CD003747.pub4
123. Venous Resource Center. Are you at risk for DVT? <https://venousdisease.com/caprini-dvt-risk-assessment/>. Accessed August 10, 2018.
124. Pannucci CJ, Bailey SH, Dreszer G, Fisher Wachtman C, Zumsteg JW, Jaber RM, Hamill JB, Hume KM, Rubin JP, Neligan PC, et al. Validation of the Caprini risk assessment model in plastic and reconstructive surgery patients. *J Am Coll Surg*. 2011;212:105–112. doi: 10.1016/j.jamcollsurg.2010.08.018
125. Shuman AG, Hu HM, Pannucci CJ, Jackson CR, Bradford CR, Bahl V. Stratifying the risk of venous thromboembolism in otolaryngology. *Otolaryngol Head Neck Surg*. 2012;146:719–724. doi: 10.1177/0194599811434383
126. Stroud W, Whitworth JM, Miklic M, Schneider KE, Finan MA, Scalici J, Reed E, Bazzett-Matabele L, Straughn JM Jr, Rocconi RP. Validation of a venous thromboembolism risk assessment model in gynecologic oncology. *Gynecol Oncol*. 2014;134:160–163. doi: 10.1016/j.ygyno.2014.04.051
127. Pannucci CJ, Rocconi RP. The limited utility of currently available venous thromboembolism risk assessment tools in gynecologic oncology patients. *Am J Obstet Gynecol*. 2016;215:673–674. doi: 10.1016/j.ajog.2016.06.052
128. Obi AT, Pannucci CJ, Nackashi A, Abdullah N, Alvarez R, Bahl V, Wakefield TW, Henke PK. Validation of the Caprini venous thromboembolism risk assessment model in critically ill surgical patients. *JAMA Surg*. 2015;150:941–948. doi: 10.1001/jamasurg.2015.1841
129. Bahl V, Hu HM, Henke PK, Wakefield TW, Campbell DA Jr, Caprini JA. A validation study of a retrospective venous thromboembolism risk scoring method. *Ann Surg*. 2010;251:344–350. doi: 10.1097/SLA.0b013e3181b7fca6
130. Pannucci CJ, Swiston L, MacDonald JK, Henke PK, Brooke BS. Individualized venous thromboembolism risk stratification using the 2005 Caprini score to identify the benefits and harms of chemoprophylaxis in surgical patients: a meta-analysis. *Ann Surg*. 2017;265:1094–1103. doi: 10.1097/SLA.0000000000002126
131. Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M, De Bon E, Tormene D, Pagnan A, Prandoni P. A risk assessment model for the identification of hospitalized medical patients at risk for venous



- thromboembolism: the Padua Prediction Score. *J Thromb Haemost*. 2010;8:2450–2457. doi: 10.1111/j.1538-7836.2010.04044.x
132. MDCalc. Padua Prediction Score for risk of VTE. <https://www.mdcalc.com/padua-prediction-score-risk-vte>. Accessed September 5, 2018.
  133. Alikhan R, Cohen AT. Heparin for the prevention of venous thromboembolism in general medical patients (excluding stroke and myocardial infarction). *Cochrane Database Syst Rev*. 2009;CD003747. doi: 10.1002/14651858.CD003747.pub2
  134. Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. *Ann Intern Med*. 2007;146:278–288. doi: 10.7326/0003-4819-146-4-200702200-00007
  135. Lloyd NS, Douketis JD, Moinuddin I, Lim W, Crowther MA. Anticoagulant prophylaxis to prevent asymptomatic deep vein thrombosis in hospitalized medical patients: a systematic review and meta-analysis. *J Thromb Haemost*. 2008;6:405–414. doi: 10.1111/j.1538-7836.2007.02847.x
  136. Grant PJ, Greene MT, Chopra V, Bernstein SJ, Hofer TP, Flanders SA. Assessing the Caprini score for risk assessment of venous thromboembolism in hospitalized medical patients. *Am J Med*. 2016;129:528–535. doi: 10.1016/j.amjmed.2015.10.027
  137. IMPROVE. In-hospital risk models. [https://www.outcomes-umassmed.org/improve/risk\\_score/index.html](https://www.outcomes-umassmed.org/improve/risk_score/index.html). Accessed November 6, 2018.
  138. Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, Hernandez AF, Gibson CM; APEX Investigators. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. *N Engl J Med*. 2016;375:534–544. doi: 10.1056/NEJMoa1601747
  139. Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Suh E, et al; MARINER Investigators. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. *N Engl J Med*. 2018;379:1118–1127. doi: 10.1056/NEJMoa1805090
  140. Freeman A, Horner T, Pendleton RC, Rondina MT. Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity. *Am J Hematol*. 2012;87:740–743. doi: 10.1002/ajh.23228
  141. Pannucci CJ, Rockwell WB, Ghanem M, Fleming KJ, Momeni A, Agarwal J. Inadequate enoxaparin dosing predicts 90-day venous thromboembolism risk among plastic surgery inpatients: an examination of enoxaparin pharmacodynamics. *Plast Reconstr Surg*. 2017;139:1009–1020. doi: 10.1097/PRS.0000000000003159
  142. Lin H, Faraklas I, Cochran A, Saffle J. Enoxaparin and antifactor Xa levels in acute burn patients. *J Burn Care Res*. 2011;32:1–5. doi: 10.1097/BCR.0b013e318204b346
  143. Cheng SS, Nordenholz K, Matero D, Pearlman N, McCarter M, Gajdos C, Hamiel C, Baer A, Luzier E, Tran ZV, et al. Standard subcutaneous dosing of unfractionated heparin for venous thromboembolism prophylaxis in surgical ICU patients leads to subtherapeutic factor Xa inhibition. *Intensive Care Med*. 2012;38:642–648. doi: 10.1007/s00134-011-2453-4
  144. Faraklas I, Ghanem M, Brown A, Cochran A. Evaluation of an enoxaparin dosing calculator using burn size and weight. *J Burn Care Res*. 2013;34:621–627. doi: 10.1097/BCR.0b013e3182a2a855
  145. Rondina MT, Wheeler M, Rodgers GM, Draper L, Pendleton RC. Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-ill patients. *Thromb Res*. 2010;125:220–223. doi: 10.1016/j.thromres.2009.02.003
  146. Nunez JM, Becher RD, Rebo GJ, Farrah JP, Borgerding EM, Stirparo JJ, Lauer C, Kilgo P, Miller PR. Prospective evaluation of weight-based prophylactic enoxaparin dosing in critically ill trauma patients: adequacy of antiXa levels is improved. *Am Surg*. 2015;81:605–609.
  147. Berndtson AE, Costantini TW, Lane J, Box K, Coimbra R. If some is good, more is better: an enoxaparin dosing strategy to improve pharmacologic venous thromboembolism prophylaxis. *J Trauma Acute Care Surg*. 2016;81:1095–1100. doi: 10.1097/TA.0000000000001142
  148. Overcash RT, Somers AT, LaCoursiere DY. Enoxaparin dosing after cesarean delivery in morbidly obese women. *Obstet Gynecol*. 2015;125:1371–1376. doi: 10.1097/AOG.0000000000000873
  149. Bickford A, Majercik S, Bledsoe J, Smith K, Johnston R, Dickerson J, White T. Weight-based enoxaparin dosing for venous thromboembolism prophylaxis in the obese trauma patient. *Am J Surg*. 2013;206:847–851. doi: 10.1016/j.amjsurg.2013.07.020
  150. Ko A, Harada MY, Barmparas G, Chung K, Mason R, Yim DA, Dhillon N, Margulies DR, Gewertz BL, Ley EJ. Association between enoxaparin dosage adjusted by anti-factor Xa trough level and clinically evident venous thromboembolism after trauma. *JAMA Surg*. 2016;151:1006–1013. doi: 10.1001/jamasurg.2016.1662
  151. Malinoski D, Jafari F, Ewing T, Ardary C, Conniff H, Bajje M, Kong A, Lekawa ME, Dolich MO, Cinat ME, et al. Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients. *J Trauma*. 2010;68:874–880. doi: 10.1097/TA.0b013e3181d32271
  152. Kopelman TR, O'Neill PJ, Pieri PG, Salomone JP, Hall ST, Quan A, Wells JR, Pressman MS. Alternative dosing of prophylactic enoxaparin in the trauma patient: is more the answer? *Am J Surg*. 2013;206:911–915. doi: 10.1016/j.amjsurg.2013.10.005
  153. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kälebo P, Christiansen AV, Hantel S, Hettiarachchi R, et al; RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. *J Thromb Haemost*. 2007;5:2178–2185. doi: 10.1111/j.1538-7836.2007.02748.x
  154. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM; ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. *N Engl J Med*. 2010;363:2487–2498. doi: 10.1056/NEJMoa1006885
  155. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, et al; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. *N Engl J Med*. 2008;358:2765–2775. doi: 10.1056/NEJMoa0800374
  156. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients: Prophylaxis in Medical Patients with Enoxaparin Study Group. *N Engl J Med*. 1999;341:793–800. doi: 10.1056/NEJM199909093411103
  157. Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, et al; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. *N Engl J Med*. 2013;368:513–523. doi: 10.1056/NEJMoa1111096
  158. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*. 2004;126(suppl):3385–4005. doi: 10.1378/chest.126.3\_suppl.3385
  159. Amin A, Stenkowski S, Lin J, Yang G. Thromboprophylaxis rates in US medical centers: success or failure? *J Thromb Haemost*. 2007;5:1610–1616. doi: 10.1111/j.1538-7836.2007.02650.x
  160. Amin A, Stenkowski S, Lin J, Yang G. Appropriate thromboprophylaxis in hospitalized cancer patients. *Clin Adv Hematol Oncol*. 2008;6:910–920.
  161. Grant PJ, Conlon A, Chopra V, Flanders SA. Use of venous thromboembolism prophylaxis in hospitalized patients. *JAMA Intern Med*. 2018;178:1122–1124. doi: 10.1001/jamainternmed.2018.2022
  162. Depietri L, Marietta M, Scarlini S, Marcacci M, Corradini E, Pietrangelo A, Ventura P. Clinical impact of application of risk assessment models (Padua Prediction Score and Improve Bleeding Score) on venous thromboembolism, major hemorrhage and health expenditure associated with pharmacologic VTE prophylaxis: a “real life” prospective and retrospective observational study on patients hospitalized in a single internal medicine unit (the STIME study). *Intern Emerg Med*. 2018;13:527–534. doi: 10.1007/s11739-018-1808-z
  163. Adams P, Riggio JM, Thomson L, Brandell-Marino R, Merli G. Clinical decision support systems to improve utilization of thromboprophylaxis: a review of the literature and experience with implementation of a computerized physician order entry program. *Hosp Pract (1995)*. 2012;40:27–39. doi: 10.3810/hp.2012.08.987
  164. Lau BD, Haut ER. Practices to prevent venous thromboembolism: a brief review. *BMJ Qual Saf*. 2014;23:187–195. doi: 10.1136/bmjqs-2012-001782
  165. Zegers M, Hesselink G, Geense W, Vincent C, Wollersheim H. Evidence-based interventions to reduce adverse events in hospitals: a systematic review of systematic reviews. *BMJ Open*. 2016;6:e012555. doi: 10.1136/bmjopen-2016-012555
  166. Borab ZM, Lanni MA, Tecce MG, Pannucci CJ, Fischer JP. Use of computerized clinical decision support systems to prevent venous thromboembolism in surgical patients: a systematic review and meta-analysis. *JAMA Surg*. 2017;152:638–645. doi: 10.1001/jamasurg.2017.0131
  167. Kahn SR, Morrison DR, Diendéré G, Piché A, Filion KB, Klil-Drori AJ, Douketis JD, Emed J, Roussin A, Tagalakis V, et al. Interventions for implementation of thromboprophylaxis in hospitalized patients at risk for venous

- thromboembolism. *Cochrane Database Syst Rev*. 2018;4:CD008201. doi: 10.1002/14651858.CD008201.pub3
168. Kucher N, Tapson VF, Goldhaber SZ; DVT FREE Steering Committee. Risk factors associated with symptomatic pulmonary embolism in a large cohort of deep vein thrombosis patients. *Thromb Haemost*. 2005;93:494–498. doi: 10.1160/TH04-09-0587
  169. Haut ER, Lau BD, Kraenzlin FS, Hobson DB, Kraus PS, Carolan HT, Haider AH, Holzmueller CG, Efron DT, Pronovost PJ, et al. Improved prophylaxis and decreased rates of preventable harm with the use of a mandatory computerized clinical decision support tool for prophylaxis for venous thromboembolism in trauma. *Arch Surg*. 2012;147:901–907. doi: 10.1001/archsurg.2012.2024
  170. Lau BD, Haider AH, Streiff MB, Lehmann CU, Kraus PS, Hobson DB, Kraenzlin FS, Zeidan AM, Pronovost PJ, Haut ER. Eliminating health care disparities with mandatory clinical decision support: the venous thromboembolism (VTE) example. *Med Care*. 2015;53:18–24. doi: 10.1097/MLR.0000000000000251
  171. Turrentine FE, Sohn MW, Wilson SL, Stanley C, Novicoff W, Sawyer RG, Williams MD. Fewer thromboembolic events after implementation of a venous thromboembolism risk stratification tool. *J Surg Res*. 2018;225:148–156. doi: 10.1016/j.jss.2018.01.013
  172. Cassidy MR, Rosenkranz P, McAneeny D. Reducing postoperative venous thromboembolism complications with a standardized risk-stratified prophylaxis protocol and mobilization program. *J Am Coll Surg*. 2014;218:1095–1104. doi: 10.1016/j.jamcollsurg.2013.12.061
  173. Shermock KM, Lau BD, Haut ER, Hobson DB, Ganetsky VS, Kraus PS, Efron DT, Lehmann CU, Pinto BL, Ross PA, et al. Patterns of non-administration of ordered doses of venous thromboembolism prophylaxis: implications for novel intervention strategies. *PLoS One*. 2013;8:e66311. doi: 10.1371/journal.pone.0066311
  174. Louis SG, Sato M, Geraci T, Anderson R, Cho SD, Van PY, Barton JS, Riha GM, Underwood S, Differding J, et al. Correlation of missed doses of enoxaparin with increased incidence of deep vein thrombosis in trauma and general surgery patients. *JAMA Surg*. 2014;149:365–370. doi: 10.1001/jamasurg.2013.3963
  175. Fanikos J, Stevens LA, Labreche M, Piazza G, Catapane E, Novack L, Goldhaber SZ. Adherence to pharmacological thromboprophylaxis orders in hospitalized patients. *Am J Med*. 2010;123:536–541. doi: 10.1016/j.amjmed.2009.11.017
  176. Popoola VO, Lau BD, Tan E, Shaffer DL, Kraus PS, Farrow NE, Hobson DB, Aboagye JK, Streiff MB, Haut ER. Nonadministration of medication doses for venous thromboembolism prophylaxis in a cohort of hospitalized patients. *Am J Health Syst Pharm*. 2018;75:392–397. doi: 10.2146/ajhp161057
  177. Popoola VO, Tavakoli F, Lau BD, Lankiewicz M, Ross P, Kraus P, Shaffer D, Hobson DB, Aboagye JK, Farrow NA, et al. Exploring the impact of route of administration on medication acceptance in hospitalized patients: implications for venous thromboembolism prevention. *Thromb Res*. 2017;160:109–113. doi: 10.1016/j.thromres.2017.10.012
  178. Patient-Centered Outcomes Research Institute. Can nurse and patient education reduce missed doses of medications to prevent blood clots in hospitals? <https://www.pcori.org/research-results/2013/can-nurse-and-patient-education-reduce-missed-doses-medications-prevent-blood>. Accessed December 5, 2018.
  179. Haut ER, Aboagye JK, Shaffer DL, Wang J, Hobson DB, Yenokyan G, Sugar EA, Kraus PS, Farrow NE, Canner JK, et al. Effect of real-time patient-centered education bundle on administration of venous thromboembolism prevention in hospitalized patients. *JAMA Netw Open*. 2018;1:e184741. doi: 10.1001/jamanetworkopen.2018.4741
  180. Michtalik HJ, Carolan HT, Haut ER, Lau BD, Streiff MB, Finkelstein J, Pronovost PJ, Durkin N, Brotman DJ. Use of provider-level dashboards and pay-for-performance in venous thromboembolism prophylaxis. *J Hosp Med*. 2015;10:172–178. doi: 10.1002/jhm.2303
  181. Hussain SA, Arsene C, Hamstra C, Woehrlin TH, Wiese-Rometsch W, White SR. Successful resident engagement in quality improvement: the Detroit Medical Center story. *J Grad Med Educ*. 2016;8:214–218. doi: 10.4300/JGME-D-15-00316.1
  182. Beckman MG, Abe K, Barnes K, Bartman B, Brady PJ, Hooper WC. Strategies and partnerships toward prevention of healthcare-associated venous thromboembolism. *J Hosp Med*. 2016;11(suppl 2):S5–S7. doi: 10.1002/jhm.2659
  183. Agency for Healthcare Research and Quality. Guide to patient safety indicators. 2003. <https://www.google.com/search?client=firefox-b-1-d&q=Guide+to+patient+safety+indicators.+2003>. Accessed September 2018.
  184. National Quality Forum. National voluntary consensus standards for prevention and care of venous thromboembolism: policy, preferred practices, and initial performance measures. 2006. [http://www.qualityforum.org/Publications/2006/12/National\\_Voluntary\\_Consensus\\_Standards\\_for\\_Prevention\\_and\\_Care\\_of\\_Venous\\_Thromboembolism\\_\\_Policy,\\_Preferred\\_Practices,\\_and\\_Initial\\_Performance\\_Measures.aspx](http://www.qualityforum.org/Publications/2006/12/National_Voluntary_Consensus_Standards_for_Prevention_and_Care_of_Venous_Thromboembolism__Policy,_Preferred_Practices,_and_Initial_Performance_Measures.aspx). Accessed September 6, 2018.
  185. Centers for Medicare & Medicaid Services. Hospital-acquired conditions. [https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalAcqCond/Hospital-Acquired\\_Conditions.html](https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalAcqCond/Hospital-Acquired_Conditions.html). Accessed September 6, 2018.
  186. Streiff MB, Haut ER. The CMS ruling on venous thromboembolism after total knee or hip arthroplasty: weighing risks and benefits. *JAMA*. 2009;301:1063–1065. doi: 10.1001/jama.301.10.1063
  187. Haut ER, Lau BD, Kraus PS, Hobson DB, Maheshwari B, Pronovost PJ, Streiff MB. Preventability of hospital-acquired venous thromboembolism. *JAMA Surg*. 2015;150:912–915. doi: 10.1001/jamasurg.2015.1340
  188. Aboagye JK, Lau BD, Schneider EB, Streiff MB, Haut ER. Linking processes and outcomes: a key strategy to prevent and report harm from venous thromboembolism in surgical patients. *JAMA Surg*. 2013;148:299–300. doi: 10.1001/jamasurg.2013.1400
  189. Lau BD, Streiff MB, Pronovost PJ, Haut ER. Venous thromboembolism quality measures fail to accurately measure quality. *Circulation*. 2018;137:1278–1284. doi: 10.1161/CIRCULATIONAHA.116.026897
  190. Pannucci CJ, Laird S, Dimick JB, Campbell DA, Henke PK. A validated risk model to predict 90-day VTE events in postsurgical patients. *Chest*. 2014;145:567–573. doi: 10.1378/chest.13-1553
  191. Birkmeyer NJ, Dimick JB, Share D, Hawasli A, English WJ, Genaw J, Finks JF, Carlin AM, Birkmeyer JD; Michigan Bariatric Surgery Collaborative. Hospital complication rates with bariatric surgery in Michigan. *JAMA*. 2010;304:435–442. doi: 10.1001/jama.2010.1034
  192. Yang AD, Hewitt DB, Blay E Jr, Kreutzer LJ, Quinn CM, Cradock KA, Prachand V, Bilimoria KY; Illinois Surgical Quality Improvement Collaborative (ISQIC). Multi-institution evaluation of adherence to comprehensive postoperative VTE chemoprophylaxis [published online January 8, 2019]. *Ann Surg*. doi: 10.1097/SLA.0000000000003124
  193. Baillie CA, Guevara JP, Boston RC, Hecht TE. A unit-based intervention aimed at improving patient adherence to pharmacological thromboprophylaxis. *BMJ Qual Saf*. 2015;24:654–660. doi: 10.1136/bmjqs-2015-003992
  194. Piazza G, Nguyen TN, Morrison R, Cios D, Hohlfelder B, Fanikos J, Paterno MD, Goldhaber SZ. Patient education program for venous thromboembolism prevention in hospitalized patients. *Am J Med*. 2012;125:258–264. doi: 10.1016/j.amjmed.2011.09.012
  195. Raskob GE, Spyropoulos AC, Zrubek J, Ageno W, Albers G, Elliott CG, Halperin J, Haskell L, Hiatt WR, Maynard GA, et al. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE: design, rationale, and clinical implications. *Thromb Haemost*. 2016;115:1240–1248. doi: 10.1160/TH15-09-0756
  196. Centers for Medicare & Medicaid Services. Core measures. <https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/QualityMeasures/Core-Measures.html>. Accessed December 6, 2018.